Therapeutic Anticoagulation with Heparin in Critically

New England Journal of Medicine
385, 777-789
DOI: 10.1056/nejmoa2103417

Citation Report

#	Article	IF	Citations
1	Low-molecular-weight heparin use in coronavirus disease 2019 is associated with curtailed viral persistence: a retrospective multicentre observational study. Cardiovascular Research, 2021, 117, 2807-2820.	3.8	21
2	Implementation of an Anticoagulation Practice Guideline for COVID-19 via a Clinical Decision Support System in a Large Academic Health System and Its Evaluation: Observational Study. JMIR Medical Informatics, 2021, 9, e30743.	2.6	3
3	Bleeding risk by intensity of anticoagulation in critically ill patients with COVIDâ€19: A retrospective cohort study. Journal of Thrombosis and Haemostasis, 2021, 19, 1533-1545.	3.8	21
4	Anticoagulation in COVID-19: reaction to the ACTION trial. Lancet, The, 2021, 397, 2226-2228.	13.7	14
5	Pulmonary Thrombosis and Thromboembolism in COVID-19. Chest, 2021, 160, 1471-1480.	0.8	92
6	COVID-19-associated coagulopathy and antithrombotic agentsâ€"lessons after 1 year. Lancet Haematology,the, 2021, 8, e524-e533.	4.6	174
7	Key summary of German national treatment guidance for hospitalized COVID-19 patients. Infection, 2022, 50, 93-106.	4.7	30
8	Heparin â€“ Messias or Verschlimmbesserung?. Journal of Thrombosis and Haemostasis, 2021, 19, 2373-2382.	3.8	8
9	Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. New England Journal of Medicine, 2021, 385, 790-802.	27.0	778
11	Thromboembolism and Bleeding in COVID-19. J, 2021, 4, 476-485.	0.9	1
12	Awake prone positioning for COVID-19 acute hypoxaemic respiratory failure: a randomised, controlled, multinational, open-label meta-trial. Lancet Respiratory Medicine,the, 2021, 9, 1387-1395.	10.7	259
13	The roles of platelets in COVID-19-associated coagulopathy and vaccine-induced immune thrombotic thrombocytopenia. Trends in Cardiovascular Medicine, 2022, 32, 1-9.	4.9	31
14	Surviving Covid-19 with Heparin?. New England Journal of Medicine, 2021, 385, 845-846.	27.0	54
15	Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. New England Journal of Medicine, 2021, 385, 777-789.	27.0	712
16	Use of novel antithrombotic agents for COVIDâ€19: Systematic summary of ongoing randomized controlled trials. Journal of Thrombosis and Haemostasis, 2021, 19, 3080-3089.	3.8	13
17	Effects of adding L-arginine orally to standard therapy in patients with COVID-19: A randomized, double-blind, placebo-controlled, parallel-group trial. Results of the first interim analysis. EClinicalMedicine, 2021, 40, 101125.	7.1	53
18	Coronavirus Disease-2019 and Heart Failure: A Scientific Statement From the Heart Failure Society of America. Journal of Cardiac Failure, 2022, 28, 93-112.	1.7	15
19	Prophylactic versus therapeutic anticoagulation for survival of patients with COVID-19 on steroid. Journal of Thrombosis and Thrombolysis, 2021, , 1.	2.1	5

#	Article	IF	Citations
20	Exogenous pulmonary surfactant in COVID-19 ARDS. The similarities to neonatal RDS suggest a new scenario for an â€˜oldâ€™ strategy. BMJ Open Respiratory Research, 2021, 8, e000867.	3.0	17
21	Cerebral Vein Thrombosis With Vaccine-Induced Immune Thrombotic Thrombocytopenia. Stroke, 2021, 52, 3045-3053.	2.0	38
22	Cardiovascular implications of the COVID-19 pandemic. Journal of Cardiology, 2022, 79, 460-467.	1.9	7
23	Lung microbiota and COVID-19 severity. Nature Microbiology, 2021, 6, 1217-1218.	13.3	10
24	Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 677-686.	3.0	45
25	Efficacy of COVID-19 Treatments: A Bayesian Network Meta-Analysis of Randomized Controlled Trials. Frontiers in Public Health, 2021, 9, 729559.	2.7	27
26	A hitchhiker's guide through the COVID-19 galaxy. Clinical Immunology, 2021, 232, 108849.	3.2	3
27	Study of Alteplase for Respiratory Failure in SARS-CoV-2 COVID-19. Chest, 2022, 161, 710-727.	0.8	36
28	Emerging and Established Histological Techniques for the Analysis of Thrombosis in COVID-19 Lungs. Frontiers in Cardiovascular Medicine, 2021, 8, 745906.	2.4	1
29	Treatments Associated with Lower Mortality among Critically Ill COVID-19 Patients: A Retrospective Cohort Study. Anesthesiology, 2021, 135, 1076-1090.	2.5	3
30	Outpatient and inpatient anticoagulation therapy and the risk for hospital admission and death among COVID-19 patients. EClinicalMedicine, 2021, 41, 101139.	7.1	19
31	Prevention of venous thromboembolism in COVID-19 patients: Is there a way forward?. Vascular Investigation and Therapy, 2021, 4, 83.	0.3	1
32	Anticoagulation is the answer in treating noncritical COVID-19 patients. Open Medicine (Poland), 2021, 16, 1486-1492.	1.3	4
34	Comprehensive Review of Cardiovascular Complications of Coronavirus Disease 2019 and Beneficial Treatments. Cardiology in Review, 2022, 30, 145-157.	1.4	11
35	Antithrombotic Therapy for Outpatients With COVID-19. JAMA - Journal of the American Medical Association, 2021, 326, 1685.	7.4	3
36	Impact of major bleeding and thrombosis on 180â€day survival in patients with severe COVIDâ€19 supported with venoâ€venous extracorporeal membrane oxygenation in the United Kingdom: a multicentre observational study. British Journal of Haematology, 2022, 196, 566-576.	2.5	27
37	Effect of Convalescent Plasma on Organ Supportâ€“Free Days in Critically Ill Patients With COVID-19. JAMA - Journal of the American Medical Association, 2021, 326, 1690.	7.4	169
38	Therapeutic versus Prophylactic Bemiparin in Hospitalized Patients with Nonsevere COVID-19 Pneumonia (BEMICOP Study): An Open-Label, Multicenter, Randomized, Controlled Trial. Thrombosis and Haemostasis, 2022, 122, 295-299.	3.4	40

#	Article	IF	Citations
39	Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial. BMJ, The, 2021, 375, n2400.	6.0	250
40	The Value of Thromboelastography (TEG) in COVID-19 Critical Illness as Illustrated by a Case Series. Journal of Cardiothoracic and Vascular Anesthesia, 2022, 36, 2536-2543.	1.3	4
41	Antiplatelet therapy and outcome in COVID-19: the Health Outcome Predictive Evaluation Registry. Heart, 2022, 108, 130-136.	2.9	49
42	What went wrong: A reckoning of Canadaâ€™s contributions to evidence-based medicine through clinical trials during the COVID-19 pandemic. Jammi, 2021, 6, 241-244.	0.5	2
43	Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19. Journal of the American College of Cardiology, 2021, 78, 1635-1654.	2.8	42
44	Complications of Critical COVID-19. Chest, 2022, 161, 989-998.	0.8	14
45	Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19. JAMA Internal Medicine, 2021, 181, 1612.	5.1	326
46	Age-adjusted D-dimer cutoffs to guide anticoagulation in COVID-19 â€“ Authors' reply. Lancet, The, 2021, 398, 1304.	13.7	0
48	Anticoagulant Therapy in Patients Hospitalized With COVID-19. JAMA Internal Medicine, 2021, 181, 1621.	5.1	11
49	Role of neutrophils, platelets, and extracellular vesicles and their interactions in COVIDâ€19â€associated thrombopathy. Journal of Thrombosis and Haemostasis, 2022, 20, 17-31.	3.8	45
50	Glucocorticoid Dose in COVID-19. JAMA - Journal of the American Medical Association, 2021, 326, 1801.	7.4	8
51	Pre-admission acetylsalicylic acid therapy and impact on in-hospital outcome in COVID-19 patients: The ASA-CARE study. International Journal of Cardiology, 2021, 344, 240-245.	1.7	17
52	PICO Questions and DELPHI Methodology for the Management of Venous Thromboembolism Associated with COVID-19. Viruses, 2021, 13, 2128.	3.3	4
53	Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19. JAMA - Journal of the American Medical Association, 2021, 326, 1703.	7.4	186
54	Pre-admission anticoagulant therapy and mortality in hospitalized COVID-19 patients: A retrospective cohort study. Thrombosis Research, 2021, 208, 35-38.	1.7	1
55	SOFA Score as a Reliable Tool to Detect High Risk for Venous Thrombosis in Patients With Critical Stage SARS-CoV-2. Frontiers in Cardiovascular Medicine, 2021, 8, 729298.	2.4	3
56	A Case of COVID-19-Associated Free-Floating Aortic Thrombus Successfully Treated with Thrombectomy. American Journal of Case Reports, 2021, 22, e933225.	0.8	6
57	Caring for Hospitalized COVID-19 Patients: From Hypes and Hopes to Doing the Simple Things First. American Journal of Tropical Medicine and Hygiene, 2021, , .	1.4	1

#	Article	IF	Citations
58	Significance of MPV, RDW and PDW with the Severity and Mortality of COVID-19 and Effects of Acetylsalicylic Acid Use. Clinical and Applied Thrombosis/Hemostasis, 2021, 27, 107602962110488.	1.7	9
61	Dilemma of Anticoagulation Therapy in Mild or Asymptomatic COVID-19 Cases. Cureus, 2021, 13, e19291.	0.5	2
62	Hostâ€modifying drugs against <scp>COVID</scp>â€19: some successes, but not yet the breakthrough. Environmental Microbiology, 2021, 23, 7257-7270.	3.8	0
63	Pathogenic Basis of Thromboinflammation and Endothelial Injury in COVID-19: Current Findings and Therapeutic Implications. International Journal of Molecular Sciences, 2021, 22, 12081.	4.1	21
64	COVID-19 associated coagulopathy: Mechanisms and host-directed treatment. American Journal of the Medical Sciences, 2022, 363, 465-475.	1.1	16
65	COVID-19 critical illness in pregnancy. Obstetric Medicine, 2022, 15, 220-224.	1.1	3
66	Clinical practice guideline: Recommendations on the in-hospital treatment of patients with COVID-19. Deutsches Ärzteblatt International, 2021, , .	0.9	15
67	Arterial and Venous Thrombosis Complicated in COVID-19: A Retrospective Single Center Analysis in Japan. Frontiers in Cardiovascular Medicine, 2021, 8, 767074.	2.4	20
68	Therapeutic Anticoagulation with Heparin in Patients with Covid-19. New England Journal of Medicine, 2021, 385, 2013-2014.	27.0	1
69	ESCMID COVID-19 living guidelines: drug treatment and clinical management. Clinical Microbiology and Infection, 2022, 28, 222-238.	6.0	103
70	Incidence and effects of deep vein thrombosis on the outcome of patients with coronavirus disease 2019 infection. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 2022, 10, 803-810.	1.6	5
71	Intermediate-to-therapeutic versus prophylactic anticoagulation for coagulopathy in hospitalized COVID-19 patients: a systemic review and meta-analysis. Thrombosis Journal, 2021, 19, 91.	2.1	12
72	Therapeutic-dose heparin should integrate the standard of care of moderately ill patients with COVID-19 admitted to hospital. European Heart Journal, 2022, 43, 365-366.	2.2	0
73	Novel Coronavirus Infection (COVID-19) Related Thrombotic and Bleeding Complications in Critically Ill Patients: Experience from an Academic Medical Center. Journal of Clinical Medicine, 2021, 10, 5652.	2.4	2
74	The effect of higher-intensity dosing of anticoagulation on the clinical outcomes in hospitalized patients with COVID-19: A meta-analysis of randomized controlled trials. Journal of Infection and Chemotherapy, 2022, 28, 257-265.	1.7	18
75	Thrombosis and Bleeding After Implementation of an Intermediate-Dose Prophylactic Anticoagulation Protocol in ICU Patients With COVID-19: A Multicenter Screening Study. Journal of Intensive Care Medicine, 2021, , 088506662110519.	2.8	3
76	Validation of a Prognostic Score to Identify Hospitalized Patients with COVID-19 at Increased Risk for Bleeding. Viruses, 2021, 13, 2278.	3.3	10
77	Anticoagulant therapy for COVID-19: What we have learned and what are the unanswered questions?. European Journal of Internal Medicine, 2022, 96, 13-16.	2.2	9

#	Article	IF	Citations
79	Coronavirus disease 2019 and cardiovascular diseases. Current Opinion in Anaesthesiology, 2021, Publish Ahead of Print, .	2.0	5
80	Daily Monitoring of D-Dimer Allows Outcomes Prediction in COVID-19. TH Open, 2022, 06, e21-e25.	1.4	9
81	Coagulopathies in Intensive Care Medicine: Balancing Act between Thrombosis and Bleeding. Journal of Clinical Medicine, 2021, 10, 5369.	2.4	7
82	High versus Standard Intensity of Thromboprophylaxis in Hospitalized Patients with COVID-19: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine, 2021, 10, 5549.	2.4	13
83	Prevention and management of thrombosis in hospitalised patients with COVID-19 pneumonia. Lancet Respiratory Medicine,the, 2022, 10, 214-220.	10.7	37
84	Intubation to Nowhere in COVID-19. Mayo Clinic Proceedings, 2022, 97, 4-6.	3.0	2
85	Treatments for COVID-19: Lessons from 2020 and new therapeutic options. Current Opinion in Pharmacology, 2022, 62, 43-59.	3.5	23
87	Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet, The, 2022, 399, 143-151.	13.7	199
88	Global lessons learned from COVID-19 mass casualty incidents. British Journal of Anaesthesia, 2022, 128, e97-e100.	3.4	7
89	Cardiac inflammation and microvascular procoagulant changes are decreased in second wave compared to first wave deceased COVID-19 patients. International Journal of Cardiology, 2022, 349, 157-165.	1.7	10
90	Randomised clinical trials in critical care: past, present and future. Intensive Care Medicine, 2022, 48, 164-178.	8.2	46
91	Anticoagulant Treatment Regimens in Patients With Covidâ€19: A Metaâ€Analysis. Clinical Pharmacology and Therapeutics, 2022, 111, 614-623.	4.7	20
92	Acute Circulatory Collapse and Advanced Therapies in Patients with COVID-19 Infection. Methodist DeBakey Cardiovascular Journal, 2021, 17, 43-52.	1.0	2
93	Management of Heart Failure, Durable Left Ventricular Assist Device, and Heart Transplant Patients in the COVID-19 Era. Methodist DeBakey Cardiovascular Journal, 2021, 17, 63-72.	1.0	2
94	Rationale and design of a study to assess the safety and efficacy of rNAPc2 in COVID-19: the Phase 2b ASPEN-COVID-19 trial. American Heart Journal, 2022, 246, 136-143.	2.7	8
95	Ocular and Systemic Complications of COVID-19: Impact on Patients and Healthcare. Clinical Ophthalmology, 2022, Volume 16, 1-13.	1.8	16
96	Interpreting recent clinical studies for COVID-19: A continual process with more new data. Anaesthesia, Critical Care & Pain Medicine, 2022, 41, 101016.	1.4	3
97	Use and misuse of biomarkers and the role of D-dimer and C-reactive protein in the management of COVID-19: A post-hoc analysis of a prospective cohort study. Clinics, 2021, 76, e3547.	1.5	13

#	Article	IF	Citations
98	Current and novel biomarkers of thrombotic risk in COVID-19: a Consensus Statement from the International COVID-19 Thrombosis Biomarkers Colloquium. Nature Reviews Cardiology, 2022, 19, 475-495.	13.7	180
99	Efficacy and safety of therapeutic vs. prophylactic bemiparin in noncritically ill patients with COVID-19 pneumonia. European Journal of Internal Medicine, 2022, , .	2.2	3
100	Liver Injury in Patients Hospitalized for COVID-19: Possible Role of Therapy. Vaccines, 2022, 10, 192.	4.4	20
101	Potential therapeutic options for COVID-19: an update on current evidence. European Journal of Medical Research, 2022, 27, 6.	2.2	85
102	Clinico-histopathologic and single-nuclei RNA-sequencing insights into cardiac injury and microthrombi in critical COVID-19. JCI Insight, 2022, 7, .	5.0	14
103	Effect of P2Y12 Inhibitors on Survival Free of Organ Support Among Nonâ€“Critically Ill Hospitalized Patients With COVID-19. JAMA - Journal of the American Medical Association, 2022, 327, 227.	7.4	89
104	COVID-19Â:Âles thÃ©rapeutiques. , 2022, 1, 13-13.		0
105	Serial Thromboelastography and the Development of Venous Thromboembolism in Critically Ill Patients With COVID-19. , 2022, 4, e0618.		5
106	Anticoagulants for Hospitalized Patients With COVID-19: The Year of Randomized Controlled Trials. , 2022, 19, .		1
107	Anticoagulation in COVID-19. Lancet, The, 2022, 399, 5-7.	13.7	18
108	Thromboelastography determined dynamics of blood coagulation and its correlation with complications and outcomes in patients with coronavirus disease 2019. Research and Practice in Thrombosis and Haemostasis, 2022, 6, e12645.	2.3	5
109	A proteomic survival predictor for COVID-19 patients in intensive care. , 2022, 1, e0000007.		28
110	Intracranial Hemorrhages on Extracorporeal Membrane Oxygenation. Critical Care Medicine, 2022, Publish Ahead of Print, .	0.9	33
111	Circulating Microparticles in the Pathogenesis and Early Anticoagulation of Thrombosis in COVID-19 With Kidney Injury. Frontiers in Cell and Developmental Biology, 2021, 9, 784505.	3.7	5
112	COVID-19 and Elevated D-Dimer: A Tale of Caution. Journal of General Internal Medicine, 2022, 37, 1304-1305.	2.6	1
113	COVID-19 in the Critically Ill Pregnant Patient. Critical Care Clinics, 2022, , .	2.6	5
114	Platelets and Antiplatelet Medication in COVID-19-Related Thrombotic Complications. Frontiers in Cardiovascular Medicine, 2021, 8, 802566.	2.4	7
115	Methylprednisolone, venous thromboembolism, and association with heparin to 30Âdays in hospital survival in severe Covid-19 pneumonia. BMC Pulmonary Medicine, 2022, 22, 6.	2.0	5

#	Article	IF	Citations
116	COVID-19 and Acute Kidney Injury. Critical Care Clinics, 2022, 38, 473-489.	2.6	21
117	Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial. Lancet, The, 2022, 399, 50-59.	13.7	172
118	Fibrinolytics as an ARDS Salvage Option. Chest, 2022, 161, 595-596.	0.8	0
119	Upper extremity deep vein thrombosis in COVID-19: Incidence and correlated risk factors in a cohort of non-ICU patients. PLoS ONE, 2022, 17, e0262522.	2.5	8
120	COVID-19 is associated with higher risk of venous thrombosis, but not arterial thrombosis, compared with influenza: Insights from a large US cohort. PLoS ONE, 2022, 17, e0261786.	2.5	17
121	The Impact of Age and BMI on the VWF/ADAMTS13 Axis and Simultaneous Thrombin and Plasmin Generation in Hospitalized COVID-19 Patients. Frontiers in Medicine, 2021, 8, 817305.	2.6	7
122	Anticoagulation Prior to COVID-19 Infection Has No Impact on 6 Months Mortality: A Propensity Scoreâ€“Matched Cohort Study. Journal of Clinical Medicine, 2022, 11, 352.	2.4	10
123	A guide to immunotherapy for COVID-19. Nature Medicine, 2022, 28, 39-50.	30.7	206
125	Effects of dalteparin on antiâ€Xa activities cannot be predicted in critically ill COVIDâ€19 patients. British Journal of Clinical Pharmacology, 2021, , .	2.4	4
126	Thromboprophylaxis for COVID-19-related coagulopathy: what next?. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, , .	3.0	1
127	SARSâ€CoVâ€2â€related and Covidâ€19 vaccineâ€induced thromboembolic events: A comparative review. Reviews in Medical Virology, 2022, 32, e2327.	8.3	8
128	Resilient Clinical Trial Infrastructure in Response to the COVID-19 Pandemic: Lessons Learned from the TOGETHER Randomized Platform Clinical Trial. American Journal of Tropical Medicine and Hygiene, 2022, 106, 389-393.	1.4	1
129	Nonâ€severe COVIDâ€19 is associated with endothelial damage and hypercoagulability despite pharmacological thromboprophylaxis. Journal of Thrombosis and Haemostasis, 2022, 20, 1008-1014.	3.8	18
130	Global haemostatic tests demonstrate the absence of parameters of hypercoagulability in non-hypoxic mild COVID-19 patients: a prospective matched studyâ€”Reply to comment from Muzaffar et al.. Journal of Thrombosis and Thrombolysis, 2022, , 1.	2.1	0
131	Thrombosis and fibrosis: mutually inclusive targets to combat in COVID-19. Future Science OA, 2022, 8, FSO777.	1.9	1
132	Dexamethasone Improves Cardiovascular Outcomes in Critically Ill COVID-19, a Real World Scenario Multicenter Analysis. Frontiers in Medicine, 2022, 9, 808221.	2.6	6
133	Thromboembolic complications during and after hospitalization for COVID-19: Incidence, risk factors and thromboprophylaxis. Thrombosis Update, 2022, 6, 100096.	0.9	2
134	Pattern of medication utilization in hospitalized patients with COVID-19 in three District Headquarters Hospitals in the Punjab province of Pakistan. Exploratory Research in Clinical and Social Pharmacy, 2022, 5, 100101.	1.0	8

#	Article	IF	Citations
135	Anticoagulation as a therapeutic strategy for hospitalised patients with COVID-19. Thrombosis Update, 2022, 6, 100097.	0.9	1
136	Multi-organ point-of-care ultrasound for detection of pulmonary embolism in critically ill COVID-19 patients â€“ A diagnostic accuracy study. Journal of Critical Care, 2022, 69, 153992.	2.2	5
137	Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus. European Heart Journal, 2022, 43, 1157-1172.	2.2	297
138	COVID-19 Coagulopathy: From Pathogenesis to Treatment. Acta Haematologica, 2022, 145, 282-296.	1.4	19
140	Thrombosis pathways in COVIDâ€19 versus influenzaâ€associated ARDS: a targeted proteomics approach. Journal of Thrombosis and Haemostasis, 2022, , .	3.8	4
141	Thromboprophylaxis in Patients With COVID-19. Chest, 2022, 162, 213-225.	0.8	58
142	Community-Acquired Pneumonia in Canada During Coronavirus Disease 2019. Open Forum Infectious Diseases, 2022, 9, ofac043.	0.9	4
143	Regional citrate and systemic heparin are adequate to maintain filter halfâ€life for COVIDâ€19 patients on continuous renal replacement therapy. Seminars in Dialysis, 2022, , .	1.3	2
144	American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARSâ€“CoVâ€2 and Hyperinflammation in Pediatric COVIDâ€19: Version 3. Arthritis and Rheumatology, 2022, 74, .	5.6	146
145	The association between anticoagulation and adverse outcomes after a positive SARS-CoV-2 test among older outpatients: A population-based cohort study. Thrombosis Research, 2022, 211, 114-122.	1.7	5
146	The association of anticoagulation before admission and survival of patients with COVID-19. Journal of Cardiology, 2022, 79, 489-493.	1.9	4
147	Therapeutic Options for Coronavirus Disease 2019 (COVID-19): Where Are We Now?. Current Infectious Disease Reports, 2021, 23, 28.	3.0	5
148	Real-Life Effectiveness and Safety of Baricitinib as Adjunctive to Standard-of-Care Treatment in Hospitalized Patients With Severe Coronavirus Disease 2019. Open Forum Infectious Diseases, 2022, 9, ofab588.	0.9	7
149	Alveolar, Endothelial, and Organ Injury Marker Dynamics in Severe COVID-19. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 507-519.	5.6	56
150	Neck Circumference Predicts Mortality in Hospitalized COVID-19 Patients. Infectious Disease Reports, 2021, 13, 1053-1060.	3.1	3
151	Heparin and SARS-CoV-2: Multiple Pathophysiological Links. Viruses, 2021, 13, 2486.	3.3	10
152	Heparin-induced thrombocytopenia in COVID-19: A systematic review. Anesthesia: Essays and Researches, 2021, 15, 341.	0.5	4
153	Anticoagulants and corticosteroids in COVID-19: What do we know so far?. Srpski Medicinski Äasopis Lekarske Komore, 2022, 3, 62-74.	0.1	1

#	Article	IF	Citations
154	Report of Low Incidence of Thrombosis with Early Prophylaxis in Hospitalized Patients with COVID-19 from Two Saudi Tertiary Centers. Clinical and Applied Thrombosis/Hemostasis, 2022, 28, 107602962210862.	1.7	2
155	â€œMATH+â€•Multi-Modal Hospital Treatment Protocol for COVID-19 Infection: Clinical and Scientific Rationale. Journal of Clinical Medicine Research, 2022, 14, 53-79.	1.2	4
156	A year in review in Minerva Anestesiologica 2021. Critical care. Minerva Anestesiologica, 2022, 88, 89-100.	1.0	0
157	MUlticenter STudy of tissue plasminogen activator (alteplase) use in COVIDâ€19 severe respiratory failure (MUST COVID): AÂretrospective cohort study. Research and Practice in Thrombosis and Haemostasis, 2022, 6, e12669.	2.3	6
160	COVIDâ€19 and venous thromboembolism: A narrative review. Research and Practice in Thrombosis and Haemostasis, 2022, 6, e12666.	2.3	16
161	COVID-19 ARDS: One Pathogen, Multiple Phenotypes. Critical Care Clinics, 2022, , .	2.6	6
162	European Society of Cardiology Highlights: Late-breaking Trials â€“ COVID-19. European Cardiology Review, 2022, 17, e04.	2.2	0
163	Treatment Outcomes of Tocilizumab in Critically-Ill COVID-19 Patients, Single-Centre Retrospective Study. Antibiotics, 2022, 11, 241.	3.7	4
164	Anticoagulation Strategies in Critically Ill Patients With SARS-CoV-2 Infection: The Role of Direct Thrombin Inhibitors. Journal of Cardiothoracic and Vascular Anesthesia, 2022, 36, 2961-2967.	1.3	4
165	The COVID Complex: A Review of Platelet Activation and Immune Complexes in COVID-19. Frontiers in Immunology, 2022, 13, 807934.	4.8	24
166	Low versus high dose anticoagulation in patients with Coronavirus 2019 pneumonia at the time of admission to critical care units: A multicenter retrospective cohort study in the Beaumont healthcare system. PLoS ONE, 2022, 17, e0265966.	2.5	2
167	Full <I>versus</i> prophylactic-intermediate doses of anticoagulants in COVID-19: a meta-analysis. Haematologica, 2022, 107, 1933-1939.	3.5	5
168	COUNTERPOINT: Should Therapeutic Heparin Be Administered to Acutely Ill Hospitalized Patients With COVID-19? No. Chest, 2022, 161, 1448-1451.	0.8	6
171	Impact of Thromboprophylaxis Intensity on Patientsâ€™ Mortality Among Hospitalized Patients with COVID-19: A Propensity-Score Matched Study. Clinical Epidemiology, 2022, Volume 14, 361-368.	3.0	1
172	Clinical Evidence Generation During a Pandemic. Cancer Journal (Sudbury, Mass), 2022, 28, 151-156.	2.0	2
173	Cardiovascular Dysfunction in COVID-19: Association Between Endothelial Cell Injury and Lactate. Frontiers in Immunology, 2022, 13, 868679.	4.8	7
174	Cardiovascular drugs and COVIDâ€19 clinical outcomes: a systematic review and metaâ€analysis of randomized controlled trials. British Journal of Clinical Pharmacology, 2022, 88, 3577-3599.	2.4	7
175	Successful treatment of intracardiac thrombosis in the presence of fulminant myocarditis requiring ECMO associated with COVID-19. Journal of Heart and Lung Transplantation, 2022, 41, 849-851.	0.6	1

#	Article	IF	Citations
176	Oxidative stress-induced endothelial dysfunction and decreased vascular nitric oxide in COVID-19 patients. EBioMedicine, 2022, 77, 103893.	6.1	48
178	Immunothrombosis and the molecular control of tissue factor by pyroptosis: prospects for new anticoagulants. Biochemical Journal, 2022, 479, 731-750.	3.7	9
179	What Are Adaptive Platform Clinical Trials and What Role May They Have in Cardiovascular Medicine?. Circulation, 2022, 145, 629-632.	1.6	19
180	Thrombosis and coagulopathy in COVID-19 patients receiving ECMO: a narrative review of current literature. Journal of Cardiothoracic and Vascular Anesthesia, 2022, 36, 3312-3317.	1.3	6
181	Coagulation factor V is a T-cell inhibitor expressed by leukocytes in COVID-19. IScience, 2022, 25, 103971.	4.1	7
182	Anticoagulation in Patients WithÂCOVID-19. Journal of the American College of Cardiology, 2022, 79, 917-928.	2.8	35
183	Coagulopathy and Fibrinolytic Pathophysiology in COVID-19 and SARS-CoV-2 Vaccination. International Journal of Molecular Sciences, 2022, 23, 3338.	4.1	11
184	POINT: Should Therapeutic Heparin Be Administered to Acutely Ill Hospitalized Patients With COVID-19? Yes. Chest, 2022, 161, 1446-1448.	0.8	8
185	The Future of Critical Care: Optimizing Technologies and a Learning Healthcare System to Potentiate a More Humanistic Approach to Critical Care. , 2022, 4, e0659.		11
186	Coreceptor functions of cell surface heparan sulfate proteoglycans. American Journal of Physiology - Cell Physiology, 2022, 322, C896-C912.	4.6	20
187	Effect of plasma exchange on COVID-19 associated excess of von Willebrand factor and inflammation in critically ill patients. Scientific Reports, 2022, 12, 4801.	3.3	10
188	Prophylactic anticoagulation with low molecular weight heparin in COVID-19: cohort studies in Denmark and Sweden. Clinical Microbiology and Infection, 2022, 28, 1291.e1-1291.e5.	6.0	3
190	In Situ Pulmonary Thrombolysis and Perfusion Lung Angiography in Severe COVID-19 Respiratory Failure. , 2022, 4, e0670.		0
191	Efficacy of different anticoagulant doses for patients with COVID-19: a systematic review and network meta-analysis. Infection, 2022, 50, 1453-1463.	4.7	4
192	Rebuttal From Dr David Jimenez etÂal. Chest, 2022, 161, 1453-1455.	0.8	0
193	Role of Acute Thrombosis in COVID-19. Critical Care Clinics, 2022, , .	2.6	3
195	Intestinal Damage in COVID-19: SARS-CoV-2 Infection and Intestinal Thrombosis. Frontiers in Microbiology, 2022, 13, 860931.	3.5	15
196	Shining a light on platelet activation in COVIDâ€19. Journal of Thrombosis and Haemostasis, 2022, , .	3.8	3

#	Article	IF	Citations
197	Naloxegol to Prevent Constipation in ICU Adults Receiving Opioids: A Randomized Double-Blind Placebo-Controlled Pilot Trial. Critical Care Research and Practice, 2022, 2022, 1-10.	1.1	1
198	Extracardiac Prothrombotic Effects of COVID-19. Cardiology Clinics, 2022, , .	2.2	2
200	Thromboprophylaxis in COVIDâ€19: Weight and severity adjusted intensified dosing. Research and Practice in Thrombosis and Haemostasis, 2022, 6, e12683.	2.3	4
201	Challenging management dogma where evidence is non-existent, weak or outdated. Intensive Care Medicine, 2022, 48, 548-558.	8.2	10
202	D-dimer and CoV-2 spike-immune complexes contribute to the production of PGE2 and proinflammatory cytokines in monocytes. PLoS Pathogens, 2022, 18, e1010468.	4.7	7
203	COVID-19 therapeutics: Challenges and directions for the future. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2119893119.	7.1	92
204	Thromboinflammation and Antithrombotics in COVID-19. JAMA - Journal of the American Medical Association, 2022, 327, 1234.	7.4	9
205	Association between preâ€admission anticoagulation and inâ€hospital death, venous thromboembolism, and major bleeding among hospitalized <scp>COVID</scp>â€19 patients in Japan. Pharmacoepidemiology and Drug Safety, 2022, 31, 680-688.	1.9	5
206	The current status of thrombosis and anticoagulation therapy in patients with COVID-19 in Japan: From the CLOT-COVID study. Journal of Cardiology, 2022, 80, 285-291.	1.9	18
207	Effect of Antiplatelet Therapy on Survival and Organ Supportâ€"Free Days in Critically Ill Patients With COVID-19. JAMA - Journal of the American Medical Association, 2022, 327, 1247.	7.4	83
208	Influence of sex on development of thrombosis in patients with COVID-19: From the CLOT-COVID study. Thrombosis Research, 2022, 213, 173-178.	1.7	12
209	Clinical update on COVID-19 for the emergency and critical care clinician: Medical management. American Journal of Emergency Medicine, 2022, 56, 158-170.	1.6	13
210	(Acute pulmonary embolism). Cor Et Vasa, 2021, 63, 675-682.	0.1	0
212	Pre- and in-hospital anticoagulation therapy in coronavirus disease 2019 patients: a propensity-matched analysis of in-hospital outcomes. Journal of Cardiovascular Medicine, 2022, 23, 264-271.	1.5	12
214	Efficacy and Safety of Anticoagulation Treatment in COVID-19 Patient Subgroups Identified by Clinical-Based Stratification and Unsupervised Machine Learning: A Matched Cohort Study. Frontiers in Medicine, 2021, 8, 786414.	2.6	2
215	Comparison of Higher-Than-Standard to D-Dimer Driven Thromboprophylaxis in Hospitalized Patients With COVID-19. Hospital Pharmacy, 0, , 001857872110664.	1.0	1
216	Randomized trials of therapeutic heparin for COVIDâ€19: A metaâ€analysis. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12638.	2.3	39
217	Immunomonitoring of Monocyte and Neutrophil Function in Critically Ill Patients: From Sepsis and/or Trauma to COVID-19. Journal of Clinical Medicine, 2021, 10, 5815.	2.4	6

#	Article	IF	Citations
218	Risk Factors for Venous Thromboembolism in Severe COVID-19: A Study-Level Meta-Analysis of 21 Studies. International Journal of Environmental Research and Public Health, 2021, 18, 12944.	2.6	19
219	Enoxaparin for thromboprophylaxis in hospitalized COVIDâ€19 patients: The Xâ€COVIDâ€19 Randomized Trial. European Journal of Clinical Investigation, 2022, 52, e13735.	3.4	31
220	Thrombotic and Clinical Outcomes in Patients with Hematologic Malignancy and COVID-19. Clinical Lymphoma, Myeloma and Leukemia, 2021, , .	0.4	2
221	An observational study of intermediateâ€•or highâ€dose thromboprophylaxis for critically ill COVIDâ€19 patients. Acta Anaesthesiologica Scandinavica, 2022, 66, 365-374.	1.6	3
222	Clinical features and acute management of COVID-19 in adults. , 2021, , 101-123.		2
223	Prone Positioning as a Potential Risk Factor for Deep Vein Thrombosis in COVID-19 Patients: A Hypothesis Generating Observation. Journal of Clinical Medicine, 2022, 11, 103.	2.4	2
224	Venous Thrombosis and SARS-CoV-2. Hamostaseologie, 2022, 42, 240-247.	1.9	7
225	The European clinical research response to optimise treatment of patients with COVID-19: lessons learned, future perspective, and recommendations. Lancet Infectious Diseases, The, 2022, 22, e153-e158.	9.1	22
227	Safety and Efficacy of Intermediate- and Therapeutic-Dose Anticoagulation for Hospitalised Patients with COVID-19: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine, 2022, 11, 57.	2.4	11
228	COVID-19 and immunothrombosis: Pathophysiology and therapeutic implications. Critical Reviews in Oncology/Hematology, 2021, 168, 103529.	4.4	22
229	Atorvastatin versus placebo in patients with covid-19 in intensive care: randomized controlled trial. BMJ, The, 2022, 376, e068407.	6.0	30
230	Lessening Organ Dysfunction With Vitamin C (LOVIT) Trial: Statistical Analysis Plan. JMIR Research Protocols, 2022, 11, e36261.	1.0	3
231	First do no harm. Research and Practice in Thrombosis and Haemostasis, 2022, 6, e12694.	2.3	2
232	Anticoagulation as secondary prevention of massive lung thromboses in hospitalized patients with COVID-19. European Journal of Internal Medicine, 2022, 100, 21-24.	2.2	7
233	Heparanase Blockade as a Novel Dual-Targeting Therapy for COVID-19. Journal of Virology, 2022, 96, e0005722.	3.4	14
234	Preinfection Anticoagulation/Antiplatelet Therapy Does Not Influence the Outcome of COVID-19 Disease in Hospitalized Patients. American Journal of Therapeutics, 2022, Publish Ahead of Print, .	0.9	0
235	New Insights in the Occurrence of Venous Thromboembolism in Critically Ill Patients with COVID-19â€"A Large Postmortem and Clinical Analysis. Viruses, 2022, 14, 811.	3.3	3
236	COVID-19 and Cardiac Arrhythmias: a Contemporary Review. Current Treatment Options in Cardiovascular Medicine, 2022, 24, 87-107.	0.9	15

#	Article	IF	Citations
237	COVID-19 Vasculitis and vasculopathy-Distinct immunopathology emerging from the close juxtaposition of Type II Pneumocytes and Pulmonary Endothelial Cells. Seminars in Immunopathology, 2022, 44, 375-390.	6.1	15
238	Acute Arterial Occlusions in COVID-19 Times: A Comparison Study Among Patients with Acute Limb Ischemia With or Without COVID-19 Infection. Annals of Vascular Surgery, 2022, 83, 80-86.	0.9	3
239	Management of patients with SARS-CoV-2 infections with focus on patients with chronic lung diseases (as of 10 January 2022). Wiener Klinische Wochenschrift, 2022, 134, 399-419.	1.9	1
240	To Anticoagulate or Not to Anticoagulate in COVID-19: Lessons after 2 Years. Seminars in Thrombosis and Hemostasis, 2023, 49, 062-072.	2.7	13
241	Automated measurement of coagulation and fibrinolytic activation markers: Outcomes in coronavirus disease 2019 (<scp>COVID</scp>â€19) patients. International Journal of Laboratory Hematology, 2022, 44, 817-822.	1.3	3
242	Epidemiology and Management of STâ€Segmentâ€“Elevation Myocardial Infarction in Patients With COVIDâ€19: A Report From the American Heart Association COVIDâ€19 Cardiovascular Disease Registry. Journal of the American Heart Association, 2022, 11, e024451.	3.7	6
243	Evaluation of Low-Dose Aspirin use among Critically Ill Patients with COVID-19: A Multicenter Propensity Score Matched Study. Journal of Intensive Care Medicine, 2022, 37, 1238-1249.	2.8	3
244	Clinical features of thrombosis and bleeding in COVID-19. Blood, 2022, 140, 184-195.	1.4	29
245	Thromboembolic Events in Deceased Patients with Proven SARS-CoV-2 Infection: Frequency, Characteristics and Risk Factors. SSRN Electronic Journal, 0, , .	0.4	0
246	Critically ill COVID-19 patients in northeast Brazil: mortality predictors during the first and second waves including SAPS 3. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2022, 116, 1054-1062.	1.8	4
247	Ischemic Stroke and SARS-CoV-2 Infection: The Bidirectional Pathology and Risk Morbidities. Neurology International, 2022, 14, 391-405.	2.8	25
248	Oxygen-Free Days as an Outcome Measure in Clinical Trials of Therapies for COVID-19 and Other Causes of New-Onset Hypoxemia. Chest, 2022, 162, 804-814.	0.8	10
250	Use of Anticoagulants in COVID-19: A Review. American Journal of Therapeutics, 2022, 29, e425-e436.	0.9	4
251	Enoxaparin Thromboprophylaxis in Children Hospitalized for COVID-19: A Phase 2 Trial. Pediatrics, 2022, 150, .	2.1	19
252	COVID-19 in Patients with Pulmonary Hypertension: A National Prospective Cohort Study. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 573-583.	5.6	16
254	A case of severe COVID-19 with pulmonary thromboembolism related to heparin-induced thrombocytopenia during prophylactic anticoagulation therapy. Journal of Infection and Chemotherapy, 2022, , .	1.7	3
256	Venous thromboembolism in COVID-19 patients and prediction model: a multicenter cohort study. BMC Infectious Diseases, 2022, 22, 462.	2.9	17
258	Critical Care Management of Severe COVID-19 in Pregnant Patients. Cureus, 2022, 14, e24885.	0.5	0

#	Article	IF	Citations
259	Venous thromboembolism (VTE) prevention and diagnosis in COVID-19: Practice patterns and outcomes at 33 hospitals. PLoS ONE, 2022, 17, e0266944.	2.5	4
260	Anticoagulant Treatment in Severe ARDS COVID-19 Patients. Journal of Clinical Medicine, 2022, 11, 2695.	2.4	4
261	Immuno-Thrombotic Complications of COVID-19: Implications for Timing of Surgery and Anticoagulation. Frontiers in Surgery, 2022, 9, .	1.4	23
262	Plasma Proteomics of COVID-19â€“Associated Cardiovascular Complications. JACC Basic To Translational Science, 2022, 7, 425-441.	4.1	17
263	COVID-19 associated rhabdomyolysis leading to major amputation in the absence of macrovascular thrombosis. Annals of Vascular Surgery Brief Reports and Innovations, 2022, 2, 100082.	0.2	2
266	Venous and arterial thrombosis in COVID-19: An updated narrative review. Journal of Infection and Public Health, 2022, 15, 689-702.	4.1	6
267	Comparison of standard prophylactic, intermediate prophylactic and therapeutic anticoagulation in patients with severe COVID-19: protocol for the ANTICOVID multicentre, parallel-group, open-label, randomised controlled trial. BMJ Open, 2022, 12, e059383.	1.9	3
268	Evaluating Primary Endpoints for COVID-19 Therapeutic Trials to Assess Recovery. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 730-739.	5.6	10
269	Thromboembolic prevention and anticoagulant therapy during the COVID-19 pandemic: updated clinical guidance from the anticoagulation forum. Journal of Thrombosis and Thrombolysis, 2022, 54, 197-210.	2.1	29
270	Endothelial dysfunction and thrombotic events in patients with severe novel coronavirus infection COVID-19. UÄenye Zapiski Sankt-Peterburgskogo Gosudarstvennogo Medicinskogo Universiteta Im Akad I P Pavlova, 2022, 28, 38-47.	0.2	3
271	Diagnosis and management of covid-19 in pregnancy. BMJ, The, 2022, 377, e069739.	6.0	25
272	Double Jeopardy: Precapillary Pulmonary Hypertension Increases the Risk of Hospitalization and Death from COVID-19. American Journal of Respiratory and Critical Care Medicine, 2022, , .	5.6	0
273	Therapeutic anticoagulation to prevent thrombosis, coagulopathy, and mortality in severe COVIDâ€19: The Swiss COVIDâ€HEP randomized clinical trial. Research and Practice in Thrombosis and Haemostasis, 2022, 6, .	2.3	18
274	COVID-19 associated coagulopathy and thrombosis in cancer. Thrombosis Research, 2022, 213, S72-S76.	1.7	1
275	Venous Gangrene Associated with COVID-19: Successful Limb Preservation Strategies with Optimal Wound Management. Annals of Vascular Surgery Brief Reports and Innovations, 2022, , 100095.	0.2	0
276	Thromboprophylaxis and anticoagulation for inpatients with coronavirus disease 2019 in 2022 and beyond. Clinical Microbiology and Infection, 2022, , .	6.0	0
277	Dâ€dimer testing in clinical practice in the era of COVIDâ€19. Research and Practice in Thrombosis and Haemostasis, 2022, 6, e12730.	2.3	9
278	The Role of Heparin in COVID-19: An Update after Two Years of Pandemics. Journal of Clinical Medicine, 2022, 11, 3099.	2.4	13

#	Article	IF	Citations
279	Therapeutic Trends of Cerebrovascular Disease during the COVID-19 Pandemic and Future Perspectives. Journal of Stroke, 2022, 24, 179-188.	3.2	12
280	Prophylactic Anticoagulant Use and Adverse Events with Bleeding in Critically Ill COVID-19 Patients. Journal of Korean Society of Health-System Pharmacists, 2022, 39, 146-157.	0.1	0
281	Antithrombotic agents in patients with COVID-19. Cmaj, 2022, 194, E704-E704.	2.0	1
282	A multisystem, cardio-renal investigation of post-COVID-19 illness. Nature Medicine, 2022, 28, 1303-1313.	30.7	39
283	The Role of Thromboelastography in Heparin Therapy for COVID-19 Patients. Jurnal Respirasi, 2022, 8, 119-125.	0.2	0
284	SARS-CoV-2 RNA copy number is a factor associated with the mortality of COVID-19 and improves the predictive performance of mortality in severe cases.. Japanese Journal of Infectious Diseases, 2022, , .	1.2	0
285	Anticoagulation in hospitalized patients with COVID-19. Blood, 2022, 140, 809-814.	1.4	12
286	Predictors of venous thromboembolism in COVID-19 patients: results of the COVID-19 Brazilian Registry. Internal and Emergency Medicine, 0, , .	2.0	3
287	Thrombotic events in critically ill children with coronavirus disease 2019 or multisystem inflammatory syndrome in children. Current Opinion in Pediatrics, 2022, 34, 261-267.	2.0	4
288	Therapeutic-Dose vs. Prophylactic-Dose Anticoagulation Therapy for Critically Ill Patients With COVID-19 in a Practice-Based Observational Study. Circulation Journal, 2022, 86, 1137-1142.	1.6	4
289	Therapeutic anticoagulation using heparin in early phase severe coronavirus disease 2019: A retrospective study. American Journal of Emergency Medicine, 2022, 58, 84-88.	1.6	0
290	Statins and Risk of Thrombosis in Critically ill Patients with COVID-19: A Multicenter Cohort Study. Clinical and Applied Thrombosis/Hemostasis, 2022, 28, 107602962211038.	1.7	4
292	Management of Acute Respiratory Distress Syndrome in COVID-19 Patients. Acta Anaesthesiologica Belgica, 2022, 73, 5-14.	0.1	0
293	An adaptive platform trial for evaluating treatments in patients with lifeâ€threatening hemorrhage from traumatic injuries: Rationale and proposal. Transfusion, 2022, 62, .	1.6	2
294	Use of pragmatic and explanatory trial designs in acute care research: lessons from COVID-19. Lancet Respiratory Medicine,the, 2022, 10, 700-714.	10.7	22
295	New Insights into Clinical and Mechanistic Heterogeneity of the Acute Respiratory Distress Syndrome: Summary of the Aspen Lung Conference 2021. American Journal of Respiratory Cell and Molecular Biology, 2022, 67, 284-308.	2.9	9
296	Redefining critical illness. Nature Medicine, 2022, 28, 1141-1148.	30.7	136
297	COVID-19 and Thrombosis: Pathophysiological Mechanisms and Therapeutic Update. , 0, , .		1

#	Article	IF	Citations
298	Role of anticoagulation in lowering the mortality in hospitalized covid-19 patients. Journal of King Abdulaziz University, Islamic Economics, 2022, 43, 541-550.	1.1	0
299	Annals for Hospitalists Inpatient Notes - Venous Thromboembolism Prophylaxis in COVID-19: Making Sense of the Evidence. Annals of Internal Medicine, 2022, 175, HO2-HO3.	3.9	1
300	An adaptive platform trial for evaluating treatments in patients with lifeâ€threatening hemorrhage from traumatic injuries: Ethical and <scp>US</scp> regulatory considerations. Transfusion, 2022, 62, .	1.6	2
301	An adaptive platform trial for evaluating treatments in patients with lifeâ€threatening hemorrhage from traumatic injuries: Planning and execution. Transfusion, 2022, 62, .	1.6	2
302	Special Issue on â€œDisseminated Intravascular Coagulation: Current Understanding and Future Perspectivesâ€. Journal of Clinical Medicine, 2022, 11, 3315.	2.4	0
303	Effect of intermediate/high versus low dose heparin on the thromboembolic and hemorrhagic risk of unvaccinated COVID-19 patients in the emergency department. BMC Emergency Medicine, 2022, 22, .	1.9	0
304	2022 AHA/ACC Key Data Elements and Definitions for Cardiovascular and Noncardiovascular Complications of COVID-19. Journal of the American College of Cardiology, 2022, , .	2.8	7
305	Effect of heparin treatment on pulmonary embolism and in-hospital death in unvaccinated COVID-19 patients without overt deep vein thrombosis. Thrombosis Journal, 2022, 20, .	2.1	1
306	COVIDâ€19 coagulopathy â€“ what should we treat?. Experimental Physiology, 2022, 107, 749-758.	2.0	8
307	Low-molecular-weight heparin compared with unfractionated heparin in critically ill COVID-19 patients. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 2022, 10, 1128-1136.	1.6	4
308	2022 AHA/ACC Key Data Elements and Definitions for Cardiovascular and Noncardiovascular Complications of COVID-19: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards. Circulation: Cardiovascular Quality and Outcomes, 0, , .	2.2	5
309	Aspirin Therapy on Prophylactic Anticoagulation for Patients Hospitalized With COVIDâ€19: A Propensity Scoreâ€Matched Cohort Analysis of the HOPEâ€COVIDâ€19 Registry. Journal of the American Heart Association, 2022, 11, .	3.7	8
310	American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis for patients with COVID-19: March 2022 update on the use of anticoagulation in critically ill patients. Blood Advances, 2022, 6, 4975-4982.	5.2	21
311	Update June 2022: management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline. European Respiratory Journal, 2022, 60, 2200803.	6.7	22
312	Efficacy and Safety of Intensified Versus Standard Prophylactic Anticoagulation Therapy in Patients With Coronavirus Disease 2019: A Systematic Review and Meta-Analysis. Open Forum Infectious Diseases, 2022, 9, .	0.9	4
313	COVID Coagulopathy and Thrombosis: A Systematic Review. Touch Reviews in Oncology & Haematology, 2022, 18, 78.	0.2	2
314	Pharmacological Studies in Hospitalized COVID-19 Patients in Belgium: We Could Do Better. Viruses, 2022, 14, 1427.	3.3	1
315	Thromboelastometry Predicts Thromboembolic Events, Hospital Length of Stay, and Mortality in Patients with COVID-19 Infection and Mild Hypoxemia: A Prospective Observational Study. Journal of Blood Medicine, 0, Volume 13, 363-372.	1.7	1

#	Article	IF	Citations
316	Clinical applications of machine learning in the survival prediction and classification of sepsis: coagulation and heparin usage matter. Journal of Translational Medicine, 2022, 20, .	4.4	9
317	High-dose versus low-dose venous thromboprophylaxis in hospitalized patients with COVID-19: a systematic review and meta-analysis. Internal and Emergency Medicine, 2022, 17, 1817-1825.	2.0	8
318	Emerging clinical trial designs may accelerate translation in hematology: lessons from COVID-19. Blood Advances, 2022, 6, 4710-4714.	5.2	5
319	Thromboprophylactic low-molecular-weight heparin versus standard of care in unvaccinated, at-risk outpatients with COVID-19 (ETHIC): an open-label, multicentre, randomised, controlled, phase 3b trial. Lancet Haematology,the, 2022, 9, e594-e604.	4.6	38
320	The Impact of Key Secular Trends During the first Three Waves the COVID-19 Pandemic. Annals of Epidemiology, 2022, , .	1.9	2
321	Upcoming and urgent challenges in critical care research based on COVID-19 pandemic experience. Anaesthesia, Critical Care & Pain Medicine, 2022, , 101121.	1.4	2
322	The effect of low-dose and high-dose low-molecular-weight-heparin and aspirin thromboprophylaxis on clinical outcome and mortality in critical ill patients with COVID-19. Journal of King Abdulaziz University, Islamic Economics, 2022, 43, 715-722.	1.1	1
323	COVID-19 increases the risk for the onset of atrial fibrillation in hospitalized patients. Scientific Reports, 2022, 12, .	3.3	25
324	The Application of Bayesian Methods to Help Interpret the VANCO Trial Results. Journal of Orthopaedic Trauma, 2022, Publish Ahead of Print, .	1.4	2
325	ISTH guidelines for antithrombotic treatment in COVIDâ€19. Journal of Thrombosis and Haemostasis, 2022, 20, 2214-2225.	3.8	100
326	Thromboprophylaxis in people hospitalized with <scp>COVID</scp> â€19: Assessing intermediate or standard doses in a retrospective cohort study. Research and Practice in Thrombosis and Haemostasis, 2022, 6, .	2.3	0
327	Clinical Characteristics and Treatment Outcomes of COVID-19 Patients at Eka Kotebe General Hospital, Addis Ababa, Ethiopia. American Journal of Tropical Medicine and Hygiene, 2022, 107, 252-259.	1.4	1
328	Dynamics of disease characteristics and clinical management of critically ill COVID-19 patients over the time course of the pandemic: an analysis of the prospective, international, multicentre RISC-19-ICU registry. Critical Care, 2022, 26, .	5.8	11
329	Bleeding and clotting while supported with ECMO: time to move forward. Intensive Care Medicine, 0, , .	8.2	1
330	Venous Thromboembolism in Sepsis: From Bench to Bedside. Biomedicines, 2022, 10, 1651.	3.2	5
331	Optimizing the Design and Analysis of Future AKI Trials. Journal of the American Society of Nephrology: JASN, 2022, 33, 1459-1470.	6.1	17
332	Antiphospholipid antibodies and vitamin D deficiency in COVID-19 infection with and without venous or arterial thrombosis: A pilot case-control study. PLoS ONE, 2022, 17, e0269466.	2.5	3
333	Heparin Resistance in SARS-CoV-2 Infected Patients with Venous Thromboembolism. Hospital Pharmacy, 0, , 001857872211117.	1.0	1

#	Article	IF	Citations
334	Heart failure in general and cardiac transplant patients with COVID-19. World Journal of Cardiology, 2022, 14, 392-402.	1.5	0
335	3D-PAST: Risk Assessment Model for Predicting Venous Thromboembolism in COVID-19. Journal of Clinical Medicine, 2022, 11, 3949.	2.4	2
336	Good practice statements for antithrombotic therapy in the management of COVIDâ€19: Guidance from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2022, 20, 2226-2236.	3.8	23
337	Anticoagulants for thrombosis prophylaxis in acutely ill patients admitted to hospital: systematic review and network meta-analysis. BMJ, The, 0, , e070022.	6.0	7
338	The interplay between inflammation and thrombosis in COVID-19: Mechanisms, therapeutic strategies, and challenges. Thrombosis Update, 2022, 8, 100117.	0.9	1
339	Bleeding and thrombotic complications in patients with severe COVIDâ€19: A prospective observational study. Health Science Reports, 2022, 5, .	1.5	3
340	Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: An updated EASL position paper. Journal of Hepatology, 2022, 77, 1161-1197.	3.7	46
341	Adoption and Deadoption of Medications to Treat Hospitalized Patients With COVID-19. , 2022, 4, e0727.		3
342	Early antithrombotic post-discharge therapy using prophylactic DOAC or dipyridamole improves long-term survival and cardiovascular outcomes in hospitalized COVID-19 survivors. Frontiers in Cardiovascular Medicine, 0, 9, .	2.4	9
343	Therapeutic Approaches to the Neurologic Manifestations of COVID-19. Neurotherapeutics, 2022, 19, 1435-1466.	4.4	22
344	Applying Lessons Learned From COVID-19 Therapeutic Trials to Improve Future ALI/ARDS Trials. Open Forum Infectious Diseases, 2022, 9, .	0.9	6
345	Patients with myeloproliferative neoplasms and COVIDâ€19 have increased rates of arterial thrombosis. Research and Practice in Thrombosis and Haemostasis, 2022, 6, e12752.	2.3	3
346	Biomarker derived risk scores predict venous thromboembolism and major bleeding among patients with COVIDâ€19. Research and Practice in Thrombosis and Haemostasis, 2022, 6, .	2.3	1
347	Treatment of COVID-19 Pneumonia and Acute Respiratory Distress With Ramatroban, a Thromboxane A2 and Prostaglandin D2 Receptor Antagonist: A Four-Patient Case Series Report. Frontiers in Pharmacology, 0, 13, .	3.5	8
348	Thromboprophylaxis for children hospitalized with <scp>COVID</scp> â€19 and <scp>MISâ€C</scp>. Research and Practice in Thrombosis and Haemostasis, 2022, 6, .	2.3	6
349	Coagulopathy in COVID-19 and anticoagulation clinical trials. Best Practice and Research in Clinical Haematology, 2022, 35, 101377.	1.7	3
350	Cardiovascular Complications of Pregnancy-Associated COVID-19 Infections. , 2022, 1, 100057.		6
351	Ability of IMPROVE and IMPROVE-DD scores to predict outcomes in patients with severe COVID-19: a prospective observational study. Scientific Reports, 2022, 12, .	3.3	1

#	Article	IF	Citations
352	Otolaryngology consultations for COVID-19 patients: A retrospective cohort study of indications, interventions, and considerations. Auris Nasus Larynx, 2022, , .	1.2	0
353	Empiric Anticoagulation Therapy in Hospitalized COVID-19 Patients: An Evaluation of Bleeding Risk Scores Performances in Predicting Bleeding Events. Journal of Clinical Medicine, 2022, 11, 4965.	2.4	2
354	The therapeutic relevance of the Kallikrein-Kinin axis in SARS-cov-2-induced vascular pathology. Critical Reviews in Clinical Laboratory Sciences, 2023, 60, 25-40.	6.1	4
356	Effect of therapeutic versus prophylactic anticoagulation therapy on clinical outcomes in COVID-19 patients: a systematic review with an updated meta-analysis. Thrombosis Journal, 2022, 20, .	2.1	3
357	The pharmacology of anticoagulant drug treatment options in COVID-19 patients: reviewing real-world evidence in clinical practice. Expert Review of Clinical Pharmacology, 2022, 15, 1095-1105.	3.1	2
358	Clinical and Genetic Risk Factors for Acute Incident Venous Thromboembolism in Ambulatory Patients With COVID-19. JAMA Internal Medicine, 2022, 182, 1063.	5.1	48
359	Care of the Seriously Ill Patient with SARS CoV-2. Medical Clinics of North America, 2022, , .	2.5	1
360	Long COVID endotheliopathy: hypothesized mechanisms and potential therapeutic approaches. Journal of Clinical Investigation, 2022, 132, .	8.2	76
361	Handgrip strength is associated with adverse outcomes in patients hospitalized for COVID-19-associated pneumonia. Internal and Emergency Medicine, 2022, 17, 1997-2004.	2.0	8
362	A comparison of three thromboprophylaxis regimens in critically ill COVID-19 patients: An analysis of real-world data. Frontiers in Cardiovascular Medicine, 0, 9, .	2.4	0
363	Antithrombotiques chez les patients atteints de COVID-19. Cmaj, 2022, 194, E1074-E1075.	2.0	0
364	Coronavirus Disease 2019-Associated Coagulopathy. Microorganisms, 2022, 10, 1556.	3.6	8
365	Hyperkalemia: do you forget something?. Internal and Emergency Medicine, 0, , .	2.0	0
366	Deep Learningâ€“Based Time-to-Death Prediction Model for COVID-19 Patients Using Clinical Data and Chest Radiographs. Journal of Digital Imaging, 2023, 36, 178-188.	2.9	6
367	The cross-talk of lung and heart complications in COVID-19: Endothelial cells dysfunction, thrombosis, and treatment. Frontiers in Cardiovascular Medicine, 0, 9, .	2.4	5
368	Thromboprophylaxis with standard-dose vs. flexible-dose heparin for hospitalized COVID-19 patients: a target trial emulation. Journal of Clinical Epidemiology, 2022, 151, 96-103.	5.0	5
369	Therapeutic versus prophylactic heparin for thromboprophylaxis in patients with COVID-19: weighing the costs and benefits. A rapid meta-analysis of randomized controlled trials. Archives of Medical Sciences Atherosclerotic Diseases, 2022, 7, 60-62.	1.0	0
370	Plasma biomarkers associated with survival and thrombosis in hospitalized COVID-19 patients. International Journal of Hematology, 2022, 116, 937-946.	1.6	11

#	Article	IF	Citations
371	Efficacy and safety of heparin full-dose anticoagulation in hospitalized non-critically ill COVID-19 patients: a meta-analysis of multicenter randomized controlled trials. Journal of Thrombosis and Thrombolysis, 2022, 54, 420-430.	2.1	17
372	Supportive Care in Patients with Critical COVID-19. Infectious Disease Clinics of North America, 2022, , .	5.1	0
373	Expert consensus on the diagnosis and treatment of severe and critical coronavirus disease 2019 (COVID-19). Journal of Intensive Medicine, 2022, 2, 199-222.	2.1	3
374	Novel Strategies for the Treatment of COVID-19. Drugs in R and D, 2022, 22, 257-262.	2.2	5
375	Diffuse alveolar damage patterns reflect the immunological and molecular heterogeneity in fatal COVID-19. EBioMedicine, 2022, 83, 104229.	6.1	13
376	Venous Thromboembolic Disease in COVID-19, Pathophysiology, Therapy and Prophylaxis. International Journal of Molecular Sciences, 2022, 23, 10372.	4.1	3
377	Occurrence of Thromboembolic Events and Mortality Among Hospitalized Coronavirus 2019 Patients: Large Observational Cohort Study of Electronic Health Records. TH Open, 2022, 06, e408-e420.	1.4	5
379	Clinical, laboratory and immunohistochemical characterization of in situ pulmonary arterial thrombosis in fatal COVID-19. Thrombosis Research, 2022, 219, 95-101.	1.7	5
380	Anticoagulation in COVID-19 patients â€“ An updated systematic review and meta-analysis. Thrombosis Research, 2022, 219, 40-48.	1.7	12
381	Effect of combining anticoagulant and glucocorticoid therapy on mortality in patients with severe COVID-19. European Journal of Inflammation, 2022, 20, 1721727X2211009.	0.5	0
382	Letter to the Editor: Venous Thromboembolism in COVID-19: Are Women Different?. Indian Journal of Cardiovascular Disease in Women WINCARS, 0, 07, 007-008.	0.1	0
383	Anti-Xa Directed Thromboprophylaxis in Critically Ill Patients with Coronavirus Disease 2019. Clinical and Applied Thrombosis/Hemostasis, 2022, 28, 107602962211163.	1.7	2
384	The diverse role of heparan sulfate and other GAGs in SARS-CoV-2 infections and therapeutics. Carbohydrate Polymers, 2023, 299, 120167.	10.2	8
385	Use of anticoagulants in patients with COVID-19: a living systematic review and meta-analysis. Jornal Brasileiro De Pneumologia, 0, , e20220041.	0.7	3
386	Standardization of Dâ€dimer reporting in the <scp>COVID</scp> â€19 era. Research and Practice in Thrombosis and Haemostasis, 2022, 6, .	2.3	1
387	Anticoagulation and Antiplatelet Therapy for Prevention of Venous and Arterial Thrombotic Events in Critically Ill Patients With COVID-19: COVID-PACT. Circulation, 2022, 146, 1344-1356.	1.6	39
388	Evolution of Approaches to Therapeutic Prevention and Treatment of the New Coronavirus Infection. Herald of the Russian Academy of Sciences, 2022, 92, 430-436.	0.6	0
389	A novel anticoagulation treatment protocol using unfractionated heparin for coronavirus disease 2019 patients in Japan, 2022. Global Health & Medicine, 2022, 4, 233-236.	1.4	1

#	Article	IF	Citations
390	Rotational thromboelastometry in critically ill COVIDâ€19 patients does not predict thrombosis. Research and Practice in Thrombosis and Haemostasis, 2022, 6, e12798.	2.3	3
391	Anticoagulation Strategies during Extracorporeal Membrane Oxygenation: A Narrative Review. Journal of Clinical Medicine, 2022, 11, 5147.	2.4	28
392	Thrombosis after SARS-CoV2 infection or COVID-19 vaccination: will a nonpathologic anti-PF4 antibody be a solution?â€"A narrative review. Journal of Bio-X Research, 2022, 5, 97-103.	0.2	1
393	COVID-19-Related ARDS: Key Mechanistic Features and Treatments. Journal of Clinical Medicine, 2022, 11, 4896.	2.4	15
394	Is It Time to Revisit Remdesivir Use for Severe COVID-19?. Indian Journal of Critical Care Medicine, 2022, 26, 983-984.	0.9	2
395	Coronavirus disease 2019 subphenotypes and differential treatment response to convalescent plasma in critically ill adults: secondary analyses of a randomized clinical trial. Intensive Care Medicine, 2022, 48, 1525-1538.	8.2	13
396	Intrapulmonary shunt and alveolar dead space in a cohort of patients with acute COVID-19 pneumonitis and early recovery. European Respiratory Journal, 2023, 61, 2201117.	6.7	8
397	Approach to Thromboprophylaxis for Prevention of Venous Thromboembolism in COVID-19: Global Updates and Clinical Insights from India. Clinics and Practice, 2022, 12, 766-781.	1.4	2
398	Efficacy and Safety of Tinzaparin in Prophylactic, Intermediate and Therapeutic Doses in Non-Critically Ill Patients Hospitalized with COVID-19: The PROTHROMCOVID Randomized Controlled Trial. Journal of Clinical Medicine, 2022, 11, 5632.	2.4	5
399	Therapeutic-dose anticoagulation or thromboprophylaxis with low-molecular-weight heparin for moderate Covid-19: meta-analysis of randomized controlled trials. Clinical and Experimental Medicine, 0, , .	3.6	2
400	Which are the optimal thromboprophylaxis strategies for hospitalized patients with COVID-19? current controversies. Vascular, 2024, 32, 220-225.	0.9	0
401	Correlating drug prescriptions with prognosis in severe COVID-19: first step towards resource management. BMC Medical Informatics and Decision Making, 2022, 22, .	3.0	1
402	Thromboprophylaxis in Patients With Cancer and COVID-19. Archivos De Bronconeumologia, 2022, 58, 744-745.	0.8	0
403	Low-Molecular-Weight Heparin Resistance and Its Viscoelastic Assessment in Critically Ill COVID-19 Patients. Seminars in Thrombosis and Hemostasis, 2022, 48, 850-857.	2.7	4
404	Saving millions of lives but some resources squandered: emerging lessons from health research system pandemic achievements and challenges. Health Research Policy and Systems, 2022, 20, .	2.8	5
405	Higher Dose Anticoagulation Cannot Prevent Disease Progression in COVID-19 Patients: A Systematic Review and Meta-Analysis. Biomedicines, 2022, 10, 2194.	3.2	0
406	Development and Implementation of the National Heart, Lung, and Blood Institute COVID-19 Common Data Elements. Journal of Clinical and Translational Science, 0, , 1-25.	0.6	0
407	Heart failure during the COVIDâ€19 pandemic: clinical, diagnostic, management, and organizational dilemmas. ESC Heart Failure, 2022, 9, 3713-3736.	3.1	12

#	Article	IF	Citations
408	AMMI Canada Practice Point: Treatments for adults with COVID-19 in 2021â€“2022. Jammi, 2022, 7, 163-169.	0.5	0
409	Hydroxychloroquine, azithromycin and methylprednisolone and in hospital survival in severe COVID-19 pneumonia. Frontiers in Pharmacology, 0, 13, .	3.5	1
411	Against Therapeutic Anticoagulation in Critically Ill COVID-19 Patients. Seminars in Thrombosis and Hemostasis, 2023, 49, 079-080.	2.7	3
412	Failed clinical trials on COVID-19 acute respiratory distress syndrome in hospitalized patients: common oversights and streamlining the development of clinically effective therapeutics. Expert Opinion on Investigational Drugs, 2022, 31, 995-1015.	4.1	4
413	COVID-19 outcomes in sickle cell disease and sickle cell trait. Best Practice and Research in Clinical Haematology, 2022, 35, 101382.	1.7	1
414	Predictors of fatal neurological complications among admitted COVID-19 patients with their implication in outcome: A Case Control study. PLoS ONE, 2022, 17, e0274485.	2.5	1
415	COVID-19 Thrombotic Complications and Therapeutic Strategies. Annual Review of Medicine, 2023, 74, 15-30.	12.2	4
416	Antiplatelet therapy for patients with COVID-19: Systematic review and meta-analysis of observational studies and randomized controlled trials. Frontiers in Medicine, 0, 9, .	2.6	10
417	The optimal anticoagulation strategy for COVID-19, prophylactic or therapeutic?: a meta-analysis, trial sequential analysis, and meta-regression of more than 27,000 participants. , 2022, 2, 148-166.		0
418	Incidence, risk factors, and clinical impact of major bleeding in hospitalized patients with COVID-19: a sub-analysis of the CLOT-COVID Study. Thrombosis Journal, 2022, 20, .	2.1	7
419	Care for adults with <scp>COVID</scp> â€19: living guidelines from the National <scp>COVID</scp> â€19 Clinical Evidence Taskforce. Medical Journal of Australia, 2022, 217, 368-378.	1.7	8
420	Prevalence of Venous Thromboembolism and Anticoagulant Use in Patients with COVID-19 in Alberta, Canada. Canadian Journal of Hospital Pharmacy, 2022, 75, 286-293.	0.1	0
421	Knowledge Gaps for Prophylactic Use of Antithrombotic Agents in Patients with COVID-19: Insights into New SARS-CoV-2 Variants, Vaccination Status, and Emerging Oral Antivirals. Thrombosis and Haemostasis, 2023, 123, 186-191.	3.4	4
423	The Comparison of Therapeutic With Prophylactic Anticoagulation on Mortality, Risk of Bleeding, and Thromboembolism in Hospitalized Patients With COVID-19: A Systematic Review. Cureus, 2022, , .	0.5	1
424	Japanese rapid/living recommendations on drug management for <scp>COVID</scp>â€19: updated guidelines (July 2022). Acute Medicine & Surgery, 2022, 9, .	1.2	6
425	Tissue plasminogen activator resistance is an early predictor of posttraumatic venous thromboembolism: A prospective study from the CLOTT research group. Journal of Trauma and Acute Care Surgery, 2022, 93, 597-603.	2.1	9
426	Trough anti-Xa activity after intermediate dose nadroparin for thrombosis prophylaxis in critically ill patients with COVID-19 and acute kidney injury. Scientific Reports, 2022, 12, .	3.3	0
427	Long pentraxin 3 (PTX3) levels predict death, intubation and thrombotic events among hospitalized patients with COVID-19. Frontiers in Immunology, 0, 13, .	4.8	5

#	Article	IF	Citations
428	From Cytokine Storm to Cytokine Breeze: Did Lessons Learned from Immunopathogenesis Improve Immunomodulatory Treatment of Moderate-to-Severe COVID-19?. Biomedicines, 2022, 10, 2620.	3.2	6
429	Colchicine and the combination of rivaroxaban and aspirin in patients hospitalised with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial. Lancet Respiratory Medicine,the, 2022, 10, 1169-1177.	10.7	14
430	COVID-19 Induces Cytokine Storm and Dysfunctional Hemostasis. Current Drug Targets, 2022, 23, 1603-1610.	2.1	3
431	Venous thromboembolism in critically ill patients with pneumonia in the <scp>preâ€COVID</scp> â€19 era: Data from a large public database. Research and Practice in Thrombosis and Haemostasis, 2022, 6, .	2.3	0
432	Current Drug Targets (CDT) special issue on Covid-19 and Coagulopathy Fibrinolysis in COVID-19: impact on clot lysis and modulation of inflammation. Current Drug Targets, 2022, 23, .	2.1	3
433	Clinical Differences and Outcomes of COVID-19 Associated Pulmonary Thromboembolism in Comparison with Non-COVID-19 Pulmonary Thromboembolism. Journal of Clinical Medicine, 2022, 11, 6011.	2.4	2
434	Incidence of Venous Thromboembolism in Hospitalized COVID-19 Patients Receiving Thromboprophylaxis. Journal of Hematology (Brossard, Quebec), 2022, 11, 167-175.	1.0	0
435	Investigation of the pharmacokinetic properties of synthetic heparan sulfate oligosaccharides. Glycobiology, 0, , .	2.5	1
436	Thrombosis-Related Loss of Arterial Lines in the First Wave of COVID-19 and Nonâ€“COVID-19 Intensive Care Unit Patients. Anesthesia and Analgesia, 0, Publish Ahead of Print, .	2.2	1
437	Prospects for the Use of Marine Sulfated Fucose-Rich Polysaccharides in Treatment and Prevention of COVID-19 and Post-COVID-19 Syndrome. Russian Journal of Bioorganic Chemistry, 2022, 48, 1109-1122.	1.0	2
439	Subgroup analyses in venous thromboembolism trials reporting pharmacological interventions: A systematic review. Thrombosis Research, 2023, 232, 151-159.	1.7	1
440	COVID-19-Associated Pulmonary Embolism: Review of the Pathophysiology, Epidemiology, Prevention, Diagnosis, and Treatment. Seminars in Thrombosis and Hemostasis, 2023, 49, 816-832.	2.7	12
441	Treatment of severe COVID-19: an evolving paradigm. Expert Opinion on Pharmacotherapy, 2022, 23, 1887-1891.	1.8	5
442	Inflammatory and Hemostatic Markers in COVID-19 Patients with Arterial Thrombosis Are Significantly Lower at Hospital Admission than in COVID-19 Patients without Thrombosis. Viruses, 2022, 14, 2330.	3.3	0
443	Drugs for the prevention and treatment of COVID-19 and its complications: An update on what we learned in the past 2 years. Frontiers in Pharmacology, 0, 13, .	3.5	8
444	Therapeutic advances in COVID-19. Nature Reviews Nephrology, 2023, 19, 38-52.	9.6	67
445	Practical Recommendations for Optimal Thromboprophylaxis in Patients with COVID-19: A Consensus Statement Based on Available Clinical Trials. Journal of Clinical Medicine, 2022, 11, 5997.	2.4	13
446	Bivalirudin vs. Enoxaparin in Intubated COVID-19 Patients: A Pilot Multicenter Randomized Controlled Trial. Journal of Clinical Medicine, 2022, 11, 5992.	2.4	2

#	Article	IF	Citations
447	Association between Thrombin Generation and Clinical Characteristics in COVID-19 Patients. Acta Haematologica, 2023, 146, 151-160.	1.4	0
448	COVID-19 Therapeutics and Considerations for Pregnancy. Obstetrics and Gynecology Clinics of North America, 2022, , .	1.9	0
450	Thromboembolic and bleeding events in <scp>ICU</scp> patients with <scp>COVID</scp> â€19 â€a nationwide, observational study. Acta Anaesthesiologica Scandinavica, 0, , .	1.6	3
451	COVID tracheostomy complications: A scoping review. Journal of Laryngology and Otology, 0, , 1-31.	0.8	0
452	Modulation of thromboinflammation in hospitalized COVIDâ€19 patients with aprotinin, low molecular weight heparin, and anakinra: The DAWnâ€Antico study. Research and Practice in Thrombosis and Haemostasis, 2022, 6, e12826.	2.3	2
453	Therapeutic vs prophylactic anticoagulation in COVID-19 patients: a systematic review and meta-analysis of real-world studies. Minerva Cardiology and Angiology, 0, , .	0.7	1
454	Indian Society of Critical Care Medicine Consensus Statement for Prevention of Venous Thromboembolism in the Critical Care Unit. Indian Journal of Critical Care Medicine, 2022, 26, S51-S65.	0.9	0
455	Evaluating Risk: Benefit Ratio of Fat-Soluble Vitamin Supplementation to SARS-CoV-2-Infected Autoimmune and Cancer Patients: Do Vitaminâ€“Drug Interactions Exist?. Life, 2022, 12, 1654.	2.4	1
456	Machine Learning Approaches for Phenotyping in Cardiogenic Shock andÂCritical Illness. , 2022, 1, 100126.		8
457	Assessment of Healthcare Resource Utilization by Anticoagulant Heparinoid Dosage Level in Patients Hospitalized with COVID-19. Clinical and Applied Thrombosis/Hemostasis, 2022, 28, 107602962211378.	1.7	0
458	Coagulation Abnormalities in Patients with COVID-19. , 2022, , 141-156.		0
459	Venous thromboembolism: Why is it still a significant health problem?. Advances in Medical Sciences, 2023, 68, 10-20.	2.1	3
460	Prevalence and Risk Factors of Venous Thromboembolism in Critically Ill Patients with Severe COVID-19 and the Association between the Dose of Anticoagulants and Outcomes. The Journal of Critical Care Medicine, 2022, 8, 249-258.	0.7	0
461	Pediatric Critical Care in the Twenty-first Century and Beyond. Critical Care Clinics, 2022, , .	2.6	0
464	Intensity of anticoagulant dosing in hospitalized patients with COVIDâ€19: an observational, comparative effectiveness study. Journal of Hospital Medicine, 0, , .	1.4	1
465	Analysis of Prior Aspirin Treatment on in-Hospital Outcome of Geriatric COVID-19 Infected Patients. Medicina (Lithuania), 2022, 58, 1649.	2.0	0
466	Therapeutic considerations for prevention and treatment of thrombotic events in COVID-19. Thrombosis Update, 2022, , 100126.	0.9	0
468	Pathophysiological mechanisms of thrombosis in acute and long COVID-19. Frontiers in Immunology, 0, 13, .	4.8	24

#	Article	IF	Citations
469	Life stressors significantly impact long-term outcomes and post-acute symptoms 12-months after COVID-19 hospitalization. Journal of the Neurological Sciences, 2022, 443, 120487.	0.6	13
470	Promising Drug Fondaparinux for the Treatment of COVID-19: an In Silico Analysis of Low Molecular Weight Heparin, Direct Oral Anticoagulant, and Antiplatelet Drug Interactions with Host Protease Furin. Cardiovascular Drugs and Therapy, 0, , .	2.6	1
472	Characteristics of subarachnoid hemorrhage associated with COVID-19 infection: A systematic review and descriptive analysis. Journal of Stroke and Cerebrovascular Diseases, 2023, 32, 106904.	1.6	1
473	COVID-19 signalome: Potential therapeutic interventions. Cellular Signalling, 2023, 103, 110559.	3.6	5
474	Practice of Awake Prone Positioning in Critically Ill COVID-19 Patientsâ€"Insights from the PRoAcTâ€"COVID Study. Journal of Clinical Medicine, 2022, 11, 6988.	2.4	2
475	Characteristics and Outcomes of Critically Ill Pregnant/Postpartum Women with COVID-19 Pneumonia in Western Balkans, The Republic of Srpska Report. Medicina (Lithuania), 2022, 58, 1730.	2.0	2
476	COVID-19 and Pulmonary Thrombosisâ€"An Unresolved Clinical Puzzle: A Single-Center Cohort Study. Journal of Clinical Medicine, 2022, 11, 7049.	2.4	3
477	Impact of COVID-19 on Non-Pulmonary Critical Illness: Prevalence, Clinical Manifestations, Management, and Outcomes. Clinics in Chest Medicine, 2022, , .	2.1	0
478	Hypercoagulability in critically ill patients with COVID 19, an observational prospective study. PLoS ONE, 2022, 17, e0277544.	2.5	5
479	Pathophysiology of Hypoxemia in COVID-19 Lung Disease. Clinics in Chest Medicine, 2023, 44, 239-248.	2.1	3
480	Challenges in evaluating treatments for COVID-19: The case of in-hospital anticoagulant use and the risk of adverse outcomes. Frontiers in Pharmacology, 0, 13, .	3.5	0
481	Platform trials for anaesthesia and perioperative medicine: a narrative review. British Journal of Anaesthesia, 2023, 130, 677-686.	3.4	3
482	Treatment of pregnant and early postpartum women with severe and critical COVID-19: experience at a tertiary center. European Journal of Medical Research, 2022, 27, .	2.2	1
484	The Effectiveness of the Intermediate and Therapeutic Doses of Enoxaparin in COVID-19 Patients: A Comparative Study of Factor Xa Inhibition. Acta Haematologica, 2023, 146, 137-143.	1.4	0
485	The potential impact of nanomedicine on COVID-19-induced thrombosis. Nature Nanotechnology, 2023, 18, 11-22.	31.5	6
486	The Histone Methyltransferase MLL1/KMT2A in Monocytes Drives Coronavirus-Associated Coagulopathy and Inflammation. Blood, 0, , .	1.4	2
487	Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial. JAMA - Journal of the American Medical Association, 2023, 329, 39.	7.4	64
488	ASCOT ADAPT study of COVID-19 therapeutics in hospitalised patients: an international multicentre adaptive platform trial. Trials, 2022, 23, .	1.6	4

#	Article	IF	Citations
490	AGIHO guideline on evidence-based management of COVID-19 in cancer patients: 2022 update on vaccination, pharmacological prophylaxis and therapy in light of the omicron variants. European Journal of Cancer, 2023, 181, 102-118.	2.8	2
491	COVID-19 and Pulmonary Embolism Outcomes among Hospitalized Patients in the United States: A Propensity-Matched Analysis of National Inpatient Sample. Vaccines, 2022, 10, 2104.	4.4	4
493	COVID-19 drug-induced liver injury: A recent update of the literature. World Journal of Gastroenterology, 0, 28, 6314-6327.	3.3	5
494	Thrombosis questions from the inpatient wards. Hematology American Society of Hematology Education Program, 2022, 2022, 481-490.	2.5	1
495	A Bayesian Interpretation of a Pediatric Cardiac Arrest Trial (THAPCA-OH). , 2023, 2, .		8
496	To prophylax or not, and how much and how long? Controversies in VTE prevention for medical inpatients, including COVID-19 inpatients. Hematology American Society of Hematology Education Program, 2022, 2022, 506-514.	2.5	4
497	Major Publications in the Critical Care Pharmacotherapy Literature: 2021. , 2022, 4, e0823.		1
498	Post-discharge Thromboembolic Events in COVID-19 Patients: A Review on the Necessity for Prophylaxis. Clinical and Applied Thrombosis/Hemostasis, 2023, 29, 107602962211484.	1.7	5
499	Effect of a systematic lung-protective protocol for COVID-19 pneumonia requiring invasive ventilation: A single center retrospective study. PLoS ONE, 2023, 18, e0267339.	2.5	0
500	Pulmonary Embolism After COVID-19 (Epidemiology, Influence on Prognosis, Pathogenesis, Treatment). Contemporary Cardiology, 2022, , 243-254.	0.1	0
501	Multi-marker risk assessment in patients hospitalized with COVID-19: Results from the American Heart Association COVID-19 Cardiovascular Disease Registry. American Heart Journal, 2023, 258, 149-156.	2.7	3
502	Risk Factors and Impact on Outcomes of Thrombosis in Patients with COVID-19 in Japan: From the CLOT-COVID Study. Annals of Vascular Diseases, 2023, , .	0.5	0
503	Reply to Bareille et al. Are Viscoelastometric Assays of Old Generation Ready for Disposal? Comment on â€œVolod et al. Viscoelastic Hemostatic Assays: A Primer on Legacy and New Generation Devices. J. Clin. Med. 2022, 11, 860â€• Journal of Clinical Medicine, 2023, 12, 478.	2.4	1
504	Potential long-term effects of SARS-CoV-2 infection on the pulmonary vasculature: Multilayered cross-talks in the setting of coinfections and comorbidities. PLoS Pathogens, 2023, 19, e1011063.	4.7	7
505	Predictive Value of Echocardiographic Pulmonary to Left Atrial Ratio for In-Hospital Death in Patients with COVID-19. Diagnostics, 2023, 13, 224.	2.6	0
506	Perspective Chapter: Cardiovascular Post-Acute COVID-19 Syndrome â€“ Definition, Clinical Scenarios, Diagnosis, and Management. , 0, , .		1
508	Efficacy and safety of two heparin regimens for prevention of venous thromboembolism in hospitalized patients with COVID-19: a meta-analysis. Internal and Emergency Medicine, 2023, 18, 863-877.	2.0	2
509	Omicron, Long-COVID, and the Safety of Elective Surgery for Adults and Children: Joint Guidance from the Therapeutics and Guidelines Committee of the Surgical Infection Society and the Surgery Strategic Clinical Network, Alberta Health Services. Surgical Infections, 2023, 24, 6-18.	1.4	4

#	Article	IF	Citations
511	Thromboprophylaxis in COVID-19. Medicina Interna (Bucharest, Romania: 1991), 2022, 19, 59-69.	0.0	0
513	Antithrombotic therapy in COVID-19 patients. Obstetrics, Gynecology and Reproduction, 2023, 16, 718-731.	0.5	1
514	Chronic anti-coagulation therapy reduced mortality in patients with high cardiovascular risk early in COVID-19 pandemic. Thrombosis Journal, 2023, 21, .	2.1	0
515	COVID-19 and atrial fibrillation: Intercepting lines. Frontiers in Cardiovascular Medicine, 0, 10, .	2.4	11
516	Electrical Impedance Tomography As a Bedside Diagnostic Tool for Pulmonary Embolism. , 2023, 5, e0843.		3
517	The Conundrum of Anticoagulation for Hospitalized Patients with Covid-19. , 2023, 2, .		0
518	Microvascular Thrombosis as a Critical Factor in Severe COVID-19. International Journal of Molecular Sciences, 2023, 24, 2492.	4.1	10
519	Comparison of Preprint Postings of Randomized Clinical Trials on COVID-19 and Corresponding Published Journal Articles. JAMA Network Open, 2023, 6, e2253301.	5.9	0
520	Is perioperative COVID-19 really associated with worse surgical outcomes? A nationwide COVIDSurg propensity-matched analysis. Journal of Trauma and Acute Care Surgery, 2023, 94, 513-524.	2.1	5
521	A randomized controlled trial to evaluate outcomes with Aggrenox in patients with SARS-CoV-2 infection. PLoS ONE, 2023, 18, e0274243.	2.5	0
522	Distribution of aeration and pulmonary blood volume in healthy, ARDS and COVID-19 lungs: a dual-energy computed tomography retrospective cohort study. Academic Radiology, 2023, , .	2.5	0
523	Recent advances in critical care. Medical Journal of Australia, 2023, 218, 153-156.	1.7	0
524	International platform trials: as diseases cross borders, so should trials. Lancet Infectious Diseases, The, 2023, 23, 530-531.	9.1	0
525	Effect of therapeutic anticoagulation on gas exchange in mechanically ventilated COVID-19 patients: A secondary analysis of the COVID-HEP trial. Thrombosis Research, 2023, 224, 13-16.	1.7	0
527	Thromboembolic Events in COVID-19. Contemporary Cardiology, 2022, , 201-216.	0.1	0
528	Thromboembolic events in hospitalised patients with COVID-19: ecological assessment with a scoping review. BMJ Open, 2023, 13, e066218.	1.9	3
529	The Efficacy and Safety of Prolonged Oral Anticoagulation for the Prevention of Thromboembolic Events in Patients Recovered From COVID-19 1 Year After Hospital Discharge: The SARCOV-19 Prospective Registry. Clinical and Applied Thrombosis/Hemostasis, 2023, 29, 107602962311517.	1.7	1
530	Therapeutic options in COVID-19. , 2023, , 647-672.		0

#	Article	IF	Citations
531	Heparin, Heparan Sulphate and Sepsis: Potential New Options for Treatment. Pharmaceuticals, 2023, 16, 271.	3.8	1
532	Pharmacology of Heparin and Related Drugs: An Update. Pharmacological Reviews, 2023, 75, 328-379.	16.0	16
533	MICHELLE trial: Inching towards the holy grail of post-discharge anticoagulation in Covid-19!. The National Medical Journal of India, 0, 35, 290-292.	0.3	0
535	Extracardiac Prothrombotic Effects of COVID-19. Heart Failure Clinics, 2023, 19, 213-220.	2.1	0
536	An Emerging Role for Type I Interferons as Critical Regulators of Blood Coagulation. Cells, 2023, 12, 778.	4.1	6
538	In Situ Pulmonary Arterial Thrombosis: Literature Review and Clinical Significance of a Distinct Entity. American Journal of Roentgenology, 2023, 221, 57-68.	2.2	6
540	Effects of 12Âmg vs. 6Âmg dexamethasone on thromboembolism and bleeding in patients with critical COVID-19 - a post hoc analysis of the randomized, blinded COVID STEROID 2 trial. Annals of Intensive Care, 2023, 13, .	4.6	1
541	Hemorrhage, Disseminated Intravascular Coagulopathy, and Thrombosis Complications Among Critically Ill Patients with COVID-19: An International COVID-19 Critical Care Consortium Study*. Critical Care Medicine, 2023, 51, 619-631.	0.9	7
542	Interactions between the reninâ€“angiotensinâ€“aldosterone system and COVID-19. , 2023, , 355-373.		0
543	Retroperitoneal hematoma: An unexpected complication of anticoagulant therapy in COVID-19 patients. Srpski Arhiv Za Celokupno Lekarstvo, 2023, , 23-23.	0.2	0
544	Utility of laboratory and immune biomarkers in predicting disease progression and mortality among patients with moderate to severe COVID-19 disease at a Philippine tertiary hospital. Frontiers in Immunology, 0, 14, .	4.8	0
545	Randomized Trial of Anticoagulation Strategies for Noncritically Ill Patients HospitalizedÂWithÂCOVID-19. Journal of the American College of Cardiology, 2023, 81, 1747-1762.	2.8	24
546	Treating COVID-19: Targeting the Host Response, Not the Virus. Life, 2023, 13, 712.	2.4	2
547	Assessing the effects of therapeutic combinations on SARS-CoV-2 infected patient outcomes: A big data approach. PLoS ONE, 2023, 18, e0282587.	2.5	0
549	Anti-cytokine Therapy in Critical Illness: Is There a Role?. Lessons From the ICU, 2023, , 277-297.	0.1	0
550	Atrial Fibrillation Occurring During Acute Hospitalization: A Scientific Statement From the American Heart Association. Circulation, 2023, 147, .	1.6	12
551	Assessment of the Risk of Venous Thromboembolism in Nonhospitalized Patients With COVID-19. JAMA Network Open, 2023, 6, e232338.	5.9	7
552	The effect of anti-coagulation dosage on the outcome of hospitalized COVID-19 patients in Ethiopia: a multi-center retrospective cohort study. BMC Pulmonary Medicine, 2023, 23, .	2.0	0

#	Article	IF	Citations
553	Safety and Efficacy of Different Anticoagulant Doses for Patients with COVID-19 in the ICU: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine, 2023, 12, 2222.	2.4	0
554	Retrospective Study of Thrombosis in Hospitalized Patients with COVID-19 in Rural North Carolina. North Carolina Medical Journal, 2023, 84, .	0.2	0
555	Montelukast as a potential treatment for COVID-19. Expert Opinion on Pharmacotherapy, 2023, 24, 551-555.	1.8	1
556	Immunothrombosis and COVID-19 â€' a nested post-hoc analysis from a 3186 patient cohort in a Latin American public reference hospital. Clinics, 2023, 78, 100178.	1.5	0
557	Rivaroxabana em Pacientes Ambulatoriais com COVID-19 Leve ou Moderada: FundamentaÃ§Ã£o e Desenho do Estudo CARE (CARE â€“ Coalition COVID-19 Brazil VIII). Arquivos Brasileiros De Cardiologia, 2023, 120, .	0.8	1
558	Heterogeneous Treatment Effects of Therapeutic-Dose Heparin in Patients Hospitalized for COVID-19. JAMA - Journal of the American Medical Association, 2023, 329, 1066.	7.4	25
559	Effects of Standard-Dose Prophylactic, High-Dose Prophylactic, and Therapeutic Anticoagulation in Patients With Hypoxemic COVID-19 Pneumonia. JAMA Internal Medicine, 2023, 183, 520.	5.1	11
560	Anticoagulation in Patients With COVID-19 Pneumoniaâ€"What Is the Optimal Intensity?. JAMA Internal Medicine, 2023, 183, 532.	5.1	3
561	An Evolving Understanding of the Basis and Management of Vascular Complications of COVID-19: Where Do We Go From Here?. Canadian Journal of Cardiology, 2023, 39, 865-874.	1.7	2
562	Cellular and molecular features of COVID-19 associated ARDS: therapeutic relevance. Journal of Inflammation, 2023, 20, .	3.4	2
563	D-dimer testing: A narrative review. Advances in Clinical Chemistry, 2023, , 151-223.	3.7	1
564	Approaches to Assure Similarity between Pharmaceutical Heparins from Two Different Manufacturers. Pharmaceutics, 2023, 15, 1115.	4.5	2
565	Pathophysiology of COVID-19 pneumonia and respiratory treatment. Minerva Anestesiologica, 2023, 89, .	1.0	1
566	Incidence of deep venous thrombosis in COVID-19 critically ill patients treated with intermediate-dose of heparin for thromboprophylaxis: The COVIDOP-DVT observational study. Vascular, 0, , 170853812311650.	0.9	0
567	Treatment options for patients with severe COVID-19. Global Health & Medicine, 2023, 5, 99-105.	1.4	1
568	Effect of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Supportâ€"Free Days in Patients Hospitalized With COVID-19. JAMA - Journal of the American Medical Association, 2023, 329, 1183.	7.4	19
569	Ongoing Uncertainties in Bleeding and Clotting Complications in Patients With COVID-19*. Critical Care Medicine, 2023, 51, 688-691.	0.9	0
570	Dexamethasone Modulates the Cytokine Response but Not COVID-19-Induced Coagulopathy in Critically Ill. International Journal of Molecular Sciences, 2023, 24, 7278.	4.1	4

#	Article	IF	Citations
571	Anticoagulation strategy and safety in critically ill COVID-19 patients: a French retrospective multicentre study. Thrombosis Journal, 2023, 21, .	2.1	0
573	How Electronic Medical Record Integration Can Support More Efficient Critical Care Clinical Trials. Critical Care Clinics, 2023, , .	2.6	0
574	Assessment of lung injury severity using ultrasound in critically ill COVID-19 patients in resource limited settings. Annals of Intensive Care, 2023, 13, .	4.6	0
575	Thrombosis Occurrence in COVID-19 Compared With Other Infectious Causes of ARDS: A Contemporary Cohort. Clinical and Applied Thrombosis/Hemostasis, 2023, 29, 107602962311756.	1.7	0
576	Determinants of Effect of Extracorporeal CO ₂ Removal in Hypoxemic Respiratory Failure. , 2023, 2, .		3
577	Population Pharmacokinetics and Probability of Target Attainment Analysis of Nadroparin in Different Stages of COVID-19. Clinical Pharmacokinetics, 2023, 62, 835-847.	3.5	1
578	Î³â€² fibrinogen levels as a biomarker of COVID-19 respiratory disease severity. Blood Cells, Molecules, and Diseases, 2023, 101, 102746.	1.4	3
579	Platelets and SARS-CoV-2 During COVID-19: Immunity, Thrombosis, and Beyond. Circulation Research, 2023, 132, 1272-1289.	4.5	13
580	Long-term post-acute sequelae of COVID-19 infection: a retrospective, multi-database cohort study in Hong Kong and the UK. EClinicalMedicine, 2023, 60, 102000.	7.1	27
581	Correlation between heparin <scp>antiâ€Xa</scp> activity and thromboelastography in adult critically ill <scp>COVID</scp>â€19 patients. Pharmacotherapy, 0, , .	2.6	0
582	Comparison of thrombotic and clinical outcomes in SARS-CoV-2-pneumonia versus other viral pneumonia in an urban academic medical center. Heart and Lung: Journal of Acute and Critical Care, 2023, 61, 153-157.	1.6	1
583	Impact of thromboprophylaxis on hospital acquired thrombosis following discharge in patients admitted with <scp>COVID</scp>â€19: Multicentre observational study in the <scp>UK</scp>. British Journal of Haematology, 2023, 202, 485-497.	2.5	3
584	A randomized controlled trial to investigate the use of acute coronary syndrome therapy in patients hospitalized with COVID-19: the COVID-19 Acute Coronary Syndrome trial. Journal of Thrombosis and Haemostasis, 2023, 21, 2213-2222.	3.8	1
585	The standard of care is standard for a reason: Commentary on â€œOptimal dosing of heparin for prophylactic anticoagulation in critically ill COVID-19 patients: A systematic review and Meta-analysis of randomized clinical trialsâ€• Journal of Critical Care, 2023, 77, 154345.	2.2	0
586	Clinical characteristics of COVID-19 associated vasculopathic diseases. Thrombosis Journal, 2023, 21, .	2.1	0
587	Optimal dosing of heparin for prophylactic anticoagulation in critically ill COVID-19 patients a systematic review and meta-analysis of randomized controlled trials. Journal of Critical Care, 2023, 77, 154344.	2.2	2
588	Effect of P2Y12 Inhibitors on Organ Supportâ€“Free Survival in Critically Ill Patients Hospitalized for COVID-19. JAMA Network Open, 2023, 6, e2314428.	5.9	4
589	Use of anticoagulants in patients with COVID-19: an update of a living systematic review and meta-analysis. Jornal Brasileiro De Pneumologia, 0, , e20230095.	0.7	0

#	Article	IF	Citations
590	Role of hospital strain in determining outcomes for people hospitalised with COVID-19 in England. Emergency Medicine Journal, 2023, 40, 542-548.	1.0	2
591	Continuation of therapeutic dose heparin for critically ill patients with COVID-19. Intensive Care Medicine, 2023, 49, 873-875.	8.2	3
592	A Comparison of Long-Term Outcomes in Patients Managed With Venovenous Extracorporeal Membrane Oxygenation in the First and Second Waves of the COVID-19 Pandemic in the United Kingdom. Critical Care Medicine, 2023, 51, 1064-1073.	0.9	1
593	Role of Therapeutic Anticoagulation in COVID-19: The Current Situation. Hematology Reports, 2023, 15, 358-369.	0.8	4
596	Rotational Thromboelastometry (ROTEMÂ®) in Relation to Inflammatory Biomarkers and Clinical Outcome in COVID-19 Patients. Journal of Clinical Medicine, 2023, 12, 3919.	2.4	2
597	Effect of weight-adjusted intermediate-dose versus fixed-dose prophylactic anticoagulation with low-molecular-weight heparin on venous thromboembolism among noncritically and critically ill patients with COVID-19: the COVI-DOSE trial, a multicenter, randomised, open-label, phase 4 trial. EClinicalMedicine, 2023, 60, 102031.	7.1	6
598	Reduced anticoagulation strategy is associated with a lower incidence of intracerebral hemorrhage in COVID-19 patients on extracorporeal membrane oxygenation. Intensive Care Medicine Experimental, 2023, 11, .	1.9	1
599	Extra-cranial hemorrhagic complications in patients with COVID-19 infection: the experience of a secondary care COVID-19 institution. Journal of Radiological Review, 2023, 10, .	0.1	0
600	Dimethyl fumarate and 4-octyl itaconate are anticoagulants that suppress Tissue Factor in macrophages via inhibition of Type I Interferon. Nature Communications, 2023, 14, .	12.8	11
601	Anticoagulant therapy in <scp>COVID</scp>â€19: A narrative review. Clinical and Translational Science, 2023, 16, 1510-1525.	3.1	1
602	Comparison of COVID-19 Preprint and Peer-Reviewed Versions of Studies on Therapies for Critically Ill Patients. Journal of Intensive Care Medicine, 2023, 38, 1060-1067.	2.8	0
603	Effect of combination of prophylactic or therapeutic anticoagulation with aspirin on the outcomes of hospitalized COVID-19 patients: An observational retrospective study. Medicine (United States), 2023, 102, e34040.	1.0	0
604	Circulating cellular clusters are associated with thrombotic complications and clinical outcomes in COVID-19. IScience, 2023, 26, 107202.	4.1	3
605	Novel Tissue Factor Inhibition for Thromboprophylaxis in COVID-19: Primary Results of the ASPEN-COVID-19 Trial. Arteriosclerosis, Thrombosis, and Vascular Biology, 2023, 43, 1572-1582.	2.4	2
606	Antithrombotic Therapy in Arterial Thrombosis and Thromboembolism in COVID-19. Chest, 2023, 164, 1531-1550.	0.8	2
607	Low molecular weight heparin in COVID-19: benefits and concerns. Frontiers in Pharmacology, 0, 14, .	3.5	1
608	Association of blood viscosity and device-free days among hospitalized patients with COVID-19. Journal of Intensive Care, 2023, 11, .	2.9	0
609	In reply: Sex-specific outcomes in COVID-19: missing pieces of the puzzle. Canadian Journal of Anaesthesia, 2023, 70, 1110-1112.	1.6	0

#	Article	IF	Citations
612	Rivaroxaban to prevent major clinical outcomes in non-hospitalised patients with COVID-19: the CAREÂâ€“ÂCOALITION VIII randomised clinical trial. EClinicalMedicine, 2023, 60, 102004.	7.1	4
613	Interrelationship between COVID-19 and Coagulopathy: Pathophysiological and Clinical Evidence. International Journal of Molecular Sciences, 2023, 24, 8945.	4.1	1
614	COVID-19 and Cerebrovascular Disease. Seminars in Neurology, 2023, 43, 219-228.	1.4	0
615	Antithrombotic therapy in the management of hospitalised patients with COVID-19. British Journal of Hospital Medicine (London, England: 2005), 2023, 84, 1-11.	0.5	0
616	Comparison of safety and efficacy between therapeutic or intermediate versus prophylactic anticoagulation for thrombosis in COVID-19 patients: a systematic review and meta-analysis. Acute and Critical Care, 2023, 38, 160-171.	1.4	1
617	Thrombotic complications in children with Coronavirus disease 2019 and Multisystem Inflammatory Syndrome of Childhood. Journal of Thrombosis and Haemostasis, 2023, 21, 2313-2326.	3.8	5
618	Timing of invasive mechanical ventilation and death in critically ill adults with COVID-19: A multicenter cohort study. PLoS ONE, 2023, 18, e0285748.	2.5	1
619	Thrombotic and hemorrhagic complications of COVID-19 in adults hospitalized in high-income countries compared with those in adults hospitalized in low- and middle-income countries in an international registry. Research and Practice in Thrombosis and Haemostasis, 2023, 7, 102142.	2.3	0
620	Increased Thrombotic Risk in COVID-19: Evidence and Controversy. Journal of Clinical Medicine, 2023, 12, 4441.	2.4	1
621	Predictors of pulmonary embolism in hospitalized patients with COVID-19. Thrombosis Journal, 2023, 21, .	2.1	1
622	The Polyanionic Drug Suramin Neutralizes Histones and Prevents Endotheliopathy. Journal of Immunology, 0, , .	0.8	2
623	Initial therapeutic anticoagulation with rivaroxaban compared to prophylactic therapy with heparins in moderate to severe COVID-19: results of the COVID-PREVENT randomized controlled trial. Clinical Research in Cardiology, 2023, 112, 1620-1638.	3.3	2
624	Contemporary outcomes of long-term anticoagulation in COVID-19 patients: a regression matched sensitivity analysis of the national inpatient sample. Expert Review of Cardiovascular Therapy, 0, , 1-8.	1.5	0
625	Thombosis, major bleeding, and survival in COVID-19 supported by veno-venous extracorporeal membrane oxygenation in the first vs second wave: a multicenter observational study in the United Kingdom. Journal of Thrombosis and Haemostasis, 2023, 21, 2735-2746.	3.8	4
626	Functional Recovery and Nutrition Management among Severe COVID-19 Cases during Post-extubation Hospitalization: A Case Series. Progress in Rehabilitation Medicine, 2023, 8, n/a.	0.9	0
627	Anticoagulant Use During Extracorporeal Membrane Oxygenation Using Heparin and Direct Thrombin Inhibitors in COVID-19 and ARDS Patients. Journal of Extra-Corporeal Technology, 2022, 54, 223-234.	0.4	0
628	Itâ€™s in the blood: a review of the hematological system in SARS-CoV-2-associated COVID-19. Critical Reviews in Clinical Laboratory Sciences, 0, , 1-30.	6.1	3
629	Composite Interventions on Outcomes of Severely and Critically Ill Patients with COVID-19 in Shanghai, China. Microorganisms, 2023, 11, 1859.	3.6	1

#	Article	IF	Citations
630	Uncertainties about the roles of anticoagulation and microclots in postacute sequelae of severe acute respiratory syndrome coronavirus 2 infection. Journal of Thrombosis and Haemostasis, 2023, 21, 2697-2701.	3.8	3
632	COVID-19 in patients with liver disease and liver transplant: clinical implications, prevention, and management. Therapeutic Advances in Gastroenterology, 2023, 16, .	3.2	1
633	Lower respiratory tract infections treatment recommendations: An overview. Pneumon, 2023, 36, 1-11.	0.3	0
634	Coronavirus disease 2019. Intensive Care Medicine, 0, , .	8.2	0
636	The Management of COVID-19-Related Coagulopathy: A Focus on the Challenges of Metabolic and Vascular Diseases. International Journal of Molecular Sciences, 2023, 24, 12782.	4.1	1
637	Are fibrinaloid microclots a cause of autoimmunity in Long Covid and other post-infection diseases?. Biochemical Journal, 2023, 480, 1217-1240.	3.7	3
638	Management and Prevention of Venous Thromboembolism in Patients with COVID-19. Current Treatment Options in Cardiovascular Medicine, 0, , .	0.9	0
639	Proton pump inhibitors in critically ill mechanically ventilated patients with COVID-19: protocol for a substudy of the Re-EValuating the Inhibition of Stress Erosions (REVISE) Trial. Trials, 2023, 24, .	1.6	0
640	Realâ€world causal evidence for planned predictive enrichment in critical care trials: A scoping review. Acta Anaesthesiologica Scandinavica, 2024, 68, 16-25.	1.6	0
641	Research Staff COVID-19 Pandemic Survey-Results from the Prevention and Early Treatment of Acute Lung Injury (PETAL) Network. Covid, 2023, 3, 1528-1543.	1.5	0
642	Comparison of Standard Versus Intermediate Prophylaxis Dose for Venous Thromboembolism Prophylaxis in Patients Hospitalized With COVID-19 Infection. Hospital Pharmacy, 0, , .	1.0	0
643	Effects of inflammation on thrombosis and outcomes in COVID-19: secondary analysis of the ATTACC/ACTIV-4a trial. Research and Practice in Thrombosis and Haemostasis, 2023, 7, 102203.	2.3	0
644	The Prevalence of Gastrointestinal Bleeding in COVID-19 Patients: A Systematic Review and Meta-Analysis. Medicina (Lithuania), 2023, 59, 1500.	2.0	0
645	The Antiviral Activity of Varenicline against Dengue Virus Replication during the Post-Entry Stage. Biomedicines, 2023, 11, 2754.	3.2	1
646	COVID-19 and cardiovascular disease in patients with chronic kidney disease. Nephrology Dialysis Transplantation, 0, , .	0.7	2
647	Using autopsies to dissect COVID-19 pathogenesis. Nature Microbiology, 2023, 8, 1986-1994.	13.3	3
648	A retrospective multicenter cohort study of the association between anti-Factor Xa values and death, thromboembolism, and bleeding in patients with critical COVID-19. Thrombosis Journal, 2023, 21, .	2.1	0
649	Treatment Effects of Therapeutic-Dose Heparin in Patients Hospitalized for COVID-19â€"Reply. JAMA - Journal of the American Medical Association, 2023, 330, 472.	7.4	0

#	Article	IF	Citations
650	COVID-19 thromboprophylaxis. New evidence. Revista EspaÃ±ola De AnestesiologÃa Y ReanimaciÃ³n (English Edition), 2024, 71, 34-47.	0.1	0
651	A case report of spontaneous pectoral hematoma in a male with background antiplatelet therapy after severe COVID-19 infection. Thrombosis Journal, 2023, 21, .	2.1	0
652	Treatments for COVID-19. Annual Review of Medicine, 2024, 75, 145-157.	12.2	5
655	Thromboembolic complications after <scp>COVID</scp>â€19 in kidney transplant recipients. Nephrology, 2024, 29, 39-47.	1.6	0
656	Associations between COVIDâ€19 therapies and inpatient gastrointestinal bleeding: A multisite retrospective study. Journal of Medical Virology, 2023, 95, .	5.0	0
658	Venous thromboembolism in an Asian COVID-19 cohort across 3 infection wavesâ€"a retrospective observational study. Research and Practice in Thrombosis and Haemostasis, 2023, 7, 102218.	2.3	1
659	SARS-CoV-2 infection of human lung epithelial cells induces TMPRSS-mediated acute fibrin deposition. Nature Communications, 2023, 14, .	12.8	0
661	Non-bacterial thrombotic endocarditis in a patient with COVID. BMJ Case Reports, 2023, 16, e256264.	0.5	0
662	Intermediate dose enoxaparin in hospitalized patients with moderate-severe COVID-19: a pilot phase II single-arm study, INHIXACOVID19. BMC Infectious Diseases, 2023, 23, .	2.9	0
663	Simvastatin in Critically Ill Patients with Covid-19. New England Journal of Medicine, 2023, 389, 2341-2354.	27.0	4
664	Intravenous Vitamin C for Patients Hospitalized With COVID-19. JAMA - Journal of the American Medical Association, 2023, 330, 1745.	7.4	7
665	Predictive Model for Mortality in Severe COVID-19 Patients across the Six Pandemic Waves. Viruses, 2023, 15, 2184.	3.3	4
666	Alveolar Hyperoxia and Exacerbation of Lung Injury in Critically Ill SARS-CoV-2 Pneumonia. Medical Sciences (Basel, Switzerland), 2023, 11, 70.	2.9	0
667	Design and Execution of Clinical Trials in the Cardiac Intensive Care Unit. Critical Care Clinics, 2024, 40, 193-209.	2.6	0
668	From Emergence to Endemicity: A Comprehensive Review of COVID-19. Cureus, 2023, , .	0.5	1
669	Prophylactic Anticoagulation and Thrombosis in Hospitalized Patients with Clinically Stable COVID-19 at Admission: From the Practice-Based Observational Study. Annals of Vascular Diseases, 2023, , .	0.5	0
670	COVID-19 and the Concept of Thrombo-Inflammation: Review of the Relationship between Immune Response, Endothelium and Coagulation. Journal of Clinical Medicine, 2023, 12, 7245.	2.4	2
671	Thrombotic Markers in Pregnant Patients with and without SARS-CoV-2 Infection. American Journal of Perinatology, 0, , .	1.4	0

#	Article	IF	Citations
672	Rethinking coagulation: from enzymatic cascade and cell-based reactions to a convergent model involving innate immune activation. Blood, 2023, 142, 2133-2145.	1.4	1
673	What Is the Point of Bayesian Analysis?. American Journal of Respiratory and Critical Care Medicine, 2024, 209, 485-487.	5.6	1
675	The intersection of coagulation activation and inflammation after injury: What you need to know. Journal of Trauma and Acute Care Surgery, 2024, 96, 347-356.	2.1	0
676	Anticoagulant treatment and COVIDâ€19 mortality among older adults living in nursing homes in Sweden. Health Science Reports, 2023, 6, .	1.5	0
677	Therapeutic Heparin in non-ICU patients Hospitalized for COVID-19 in the ACTIV-4a Trial: Effect on 3 Month Symptoms and Quality of Life. Chest, 2023, , .	0.8	0
678	VTE prevention in medical inpatients - Current approach and controversies. Thrombosis Update, 2023, 13, 100151.	0.9	0
679	Acute Respiratory Failure From Early Pandemic COVID-19. , 2024, 2, 100030.		1
680	The effect of COVID-19 on the thromboembolic outcomes in atrial fibrillation patients in the long run. Acta Cardiologica, 0, , 1-7.	0.9	1
681	Coronavirus Disease 2019 (COVID-19) and Venous Thromboembolism During Pregnancy and Postpartum. Obstetrics and Gynecology, 2024, 143, 139-142.	2.4	0
682	Whole blood viscoelastic testing profile and mortality in patients hospitalized with acute COVID-19 pneumonia: A systematic review and meta-analysis. Thrombosis Research, 2024, 234, 21-31.	1.7	0
683	Thromboelastography-Guided Anticoagulation in Critically Ill COVID-19 Patients: Mortality and Bleeding Outcomes. Journal of Respiration, 2024, 4, 1-11.	1.1	0
685	The Ethical Obligation for Research During Public Health Emergencies: Insights From the COVID-19 Pandemic. Medicine, Health Care and Philosophy, 2024, 27, 49-70.	1.8	0
686	Clinical trials of pharmacological interventions for SARSâ€CoVâ€2 published in leading medical journals report adherence but not how it was assessed.. British Journal of Clinical Pharmacology, 0, , .	2.4	0
688	Mortality Trend of Severe COVID-19 in Under-Vaccinated Population Admitted to ICU in French Amazonia. Tropical Medicine and Infectious Disease, 2024, 9, 15.	2.3	0
689	Anticoagulation dosage strategy therapy, length of stay, and all-cause mortality in critically ill COVID-19 patients admitted to the intensive care unit. Medicine (United States), 2024, 103, e36854.	1.0	0
690	Design and implementation of the hospital airway resuscitation trial. Resuscitation Plus, 2024, 17, 100512.	1.7	0
691	COVID-19 und VTE-Prophylaxe. Springer Reference Medizin, 2024, , 1-11.	0.0	0
692	Oral Infections, SARS-CoV-2 Infection, and Autoimmunity. , 2024, , 1013-1044.		0

#	Article	IF	Citations
693	Effectiveness of Drug Repurposing and Natural Products Against SARS-CoV-2: A Comprehensive Review. Clinical Pharmacology: Advances and Applications, 0, Volume 16, 1-25.	1.2	0
694	AMMI Canada Practice Point: Updated recommendations for treatment of adults with symptomatic COVID-19 in 2023â€“2024. Jammi, 2024, 8, 245-252.	0.5	0
695	Multisite spontaneous hematomas and bleeding in critically ill Chinese patients with COVID-19: two case reports and a literature review. BMC Infectious Diseases, 2024, 24, .	2.9	1
696	Pulmonary embolism impacts clinical outcomes of intubated patients with acute respiratory distress syndrome related to COVID-19. Anaesthesia, Critical Care & Pain Medicine, 2024, 43, 101348.	1.4	0
697	Therapeutic-Dose Anticoagulation in Hospitalized Patients With COVID-19. , 2024, 3, 100779.		0
698	Heparin Dose Intensity and Organ Support-Free Days in Patients Hospitalized for COVID-19. , 2024, 3, 100780.		0
699	Understanding Heterogeneity in Acute Care Trials: Resource Availability Impacts Outcomes. American Journal of Respiratory and Critical Care Medicine, 2024, 209, 469-471.	5.6	0
700	Effect of antiplatelet therapy after COVID-19 diagnosis: A systematic review with meta-analysis and trial sequential analysis. PLoS ONE, 2024, 19, e0297628.	2.5	0
701	Uncertainties about the roles of anticoagulation and microclots in postacute sequelae of SARS-CoV-2 infection: comment from Kell etÂal.. Journal of Thrombosis and Haemostasis, 2024, 22, 565-568.	3.8	0
702	Uncertainties about the roles of anticoagulation and microclots in post-acute sequelae of SARS-CoV-2 infectionâ€”response to the letter by Kell etÂal.. Journal of Thrombosis and Haemostasis, 2024, 22, 569-571.	3.8	0
703	Transforming research to improve therapies for trauma in the twenty-first century. Critical Care, 2024, 28, .	5.8	0
704	Understanding the Evolving Pathophysiology of Coronavirus Disease 2019 and Adult Nursing Management. Critical Care Nursing Clinics of North America, 2024, , .	0.8	0
705	Tenecteplase With Concomitant Anticoagulation for Acute Respiratory Failure in Patients With COVID-19: A Randomized Controlled Trial. Cureus, 2024, , .	0.5	0
706	Investigational pharmacological agents for the treatment of ARDS. Expert Opinion on Investigational Drugs, 2024, 33, 243-277.	4.1	0
707	Venous thromboembolism prophylaxis in Asian patients with severe COVID-19: A prospective cohort study. Thrombosis Update, 2024, 14, 100162.	0.9	0
708	IL-6 and D-dimer Levels at Admission Predict Cardiac Injury and Early Mortality during SARS-CoV-2 Infection. Cardiovascular Innovations and Applications, 2024, 9, .	0.3	0
709	Impact of vaccination on the association of COVID-19 with cardiovascular diseases: An OpenSAFELY cohort study. Nature Communications, 2024, 15, .	12.8	0
710	Association between loss of hypercoagulable phenotype, clinical features and complement pathway consumption in COVID-19. Frontiers in Immunology, 0, 15, .	4.8	0

#	Article	IF	Citations
711	The Association of Anticoagulation Intensity with Outcomes in Hospitalized COVID-19 Patients. Advances in Hematology, 2024, 2024, 1-9.	1.0	0
712	2023 ISTH update of the 2022 ISTH guidelines for antithrombotic treatment in COVID-19. Journal of Thrombosis and Haemostasis, 2024, , .	3.8	0